gamma-aminobutyric acid has been researched along with Peripheral Nerve Diseases in 166 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Our goal was to compare the effects of gabapentin and pregabalin on improving sleep quality and depression among hemodialysis patients with PPN." | 9.17 | Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. ( Atalay, H; Biyik, Z; Gaipov, A; Guney, F; Solak, Y; Turk, S, 2013) |
| "To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)." | 9.14 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 9.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-imipramine significantly decreased the total pain score and daily paroxysmal pain episodes." | 9.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects." | 9.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 9.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "This study evaluated the effectiveness of gabapentin to treat cancer-related neuropathic pain." | 9.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "We conclude that gabapentin is an effective treatment for cancer-related neuropathic pain." | 9.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "To evaluate the effects of gabapentin on pain scores and opiate use." | 9.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| " A significant decrease in pain scores with gabapentin was seen in the neuropathic pain group (paired t-test, p < ." | 9.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| "Gabapentin may be a useful adjunct for treating neuropathic pain with a minimum of side effects." | 9.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| "A large case series of patients with centrally mediated pain, peripherally mediated pain, migraine, and tremor were treated in an open-label study with gabapentin (maximum of 2,700 mg/day)." | 9.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "Gabapentin offers an effective, safe alternative therapy or co-therapy for the listed painful conditions and tremor; it does not affect the metabolism of other medications and is well tolerated." | 9.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Recent studies showed effectiveness of gabapentin in improving the pain control in patients with neuropathic cancer pain, already treated with opiates." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Given the significant benefits of gabapentin and the combination of gabapentin with opioids for the treatment of neuropathic pain, randomized clinical trials are needed to establish the role of these analgesic regimens for the treatment of neuropathic cancer pain." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| " Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Randomized controlled studies of gabapentin for neuropathic pain were identified through a search of PubMed and MEDLINE from 1966 to the present using the search terms gabapentin, randomized, placebo, and pain." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "At doses of 1800 to 3600 mg/d, gabapentin was effective and well tolerated in the treatment of adults with neuropathic pain." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "This paper reviews the pharmacology and clinical effectiveness of gabapentin in the treatment of neuropathic pain." | 8.82 | Gabapentin in the treatment of neuropathic pain. ( Bennett, MI; Simpson, KH, 2004) |
| " The search terms included pregabalin, PD144723, CI-1008, gabapentin, and neuropathic pain." | 8.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "In preclinical studies, pregabalin, a structural congener of gabapentin, exhibited antinociceptive activity in animal models of neuropathic and inflammatory pain." | 8.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "This article reviews the available information on pregabalin, a new anticonvulsant for peripheral neuropathic pain." | 8.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "The involvement of voltage-dependent calcium channels and reactive oxygen species in the pathophysiology of neuropathic pain might justify the preventative administration of antioxidant enzymes, at low doses, in combination with gabapentin (GaP) to maximize its analgesic effect in an experimental model of neuropathic pain in rats." | 7.79 | Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model. ( Arcos, M; Barrios, C; Montes, F; Palanca, JM, 2013) |
| "The effect of the cyclooxygenase-2 (COX-2) inhibitor etodolac on the mechanical allodynia induced by paclitaxel was investigated in mice and compared with the effects of the nonselective COX inhibitors indomethacin and diclofenac, the selective COX-2 inhibitor celecoxib, the calcium channel α(2)δ subunit inhibitor pregabalin, the sodium channel blocker mexiletine, and the serotonin-norepinephrine reuptake inhibitor duloxetine." | 7.78 | Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. ( Banno, K; Inoue, N; Ito, S; Kotera, T; Kyoi, T; Nakamura, A; Nogawa, M; Sasagawa, T; Tajima, K; Takahashi, Y; Ueda, M; Yamashita, Y, 2012) |
| "When performing R-CHOP(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)for diffuse large B-cell lymphoma(DLBCL), neurotoxicity of vincristine(VCR)is the serious dose-limiting factor." | 7.78 | [A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma]. ( Hosokawa, A; Ito, T; Kiba, T; Kido, M; Kimura, A; Kozawa, K; Nakashima, T; Niimi, H; Ogawa, Y; Okada, Y; Okikawa, Y; Saito, A; Shintani, H; Taniguchi, T; Taniyama, K, 2012) |
| "Numerous controlled clinical trials have demonstrated the safety and efficacy of pregabalin in the treatment of neuropathic pain." | 7.77 | Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. ( Anastassiou, E; Iatrou, CA; Lyras, L; Plesia, E; Stamatiou, G; Vadalouca, A; Vafiadou, M; Vlaikidis, N, 2011) |
| "This was a non-interventional, multicentre study in which pregabalin was administered for 8 weeks, at the therapeutic dosages of 150-600 mg/day, to patients with a diagnosis of neuropathic pain." | 7.77 | Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. ( Anastassiou, E; Iatrou, CA; Lyras, L; Plesia, E; Stamatiou, G; Vadalouca, A; Vafiadou, M; Vlaikidis, N, 2011) |
| "Significant reductions in pain and pain-related sleep interference, combined with reductions in feelings of anxiety and depression, suggest that pregabalin under real-world conditions improves the overall health and well-being of patients with neuropathic pain." | 7.77 | Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. ( Anastassiou, E; Iatrou, CA; Lyras, L; Plesia, E; Stamatiou, G; Vadalouca, A; Vafiadou, M; Vlaikidis, N, 2011) |
| "To determine the utility of substitution of pregabalin (PGB) for gabapentin (GBP) therapy in the relief of neuropathic pain (NeP) in patients with peripheral neuropathy (PN)." | 7.76 | Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. ( Toth, C, 2010) |
| "Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy." | 7.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain." | 7.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "The effects of treatment with the anti-convulsant agents, lamotrigine and riluzole were compared with gabapentin in a rat experimental model of neuropathic pain." | 7.74 | A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2007) |
| " In this study, we tested the hypothesis that removal of GABAergic and glycinergic inhibitory inputs attenuates the effect of morphine on dorsal horn projection neurons and the reduced spinal GABAergic tone contributes to attenuated morphine effect in neuropathic pain." | 7.73 | Effect of morphine on deep dorsal horn projection neurons depends on spinal GABAergic and glycinergic tone: implications for reduced opioid effect in neuropathic pain. ( Chen, SR; Chen, YP; Pan, HL, 2005) |
| " When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%)." | 7.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "This study investigated the anti-allodynic and anti-oedematogenic effects of the hexanic extract, lignan-rich fraction and purified lignans from a plant used in the traditional medicine, Phyllanthus amarus, in the inflammatory and neuropathic models of nociception." | 7.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "We report a case of neutropenia occurring in a patient receiving gabapentin for neuropathic pain." | 7.72 | Neutropenia occurring after starting gabapentin for neuropathic pain. ( Derbyshire, E; Martin, D, 2004) |
| "The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain." | 7.71 | Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002) |
| " The aim of this study was to see whether low-dose gabapentin is effective in treating cancer-related neuropathic pain when combined with low-dose imipramine." | 6.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects." | 6.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Painful neuropathic conditions of cancer pain often show little response to nonopioid and opioid analgesics but may be eased by antidepressants and anticonvulsants." | 6.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 6.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| " Patients in group B who were receiving gabapentin continued this treatment up to a maximum daily dosage of 2400 mg during the observation period." | 6.74 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "Multimodal pain is comprised of nociceptive/inflammatory and neuropathic components." | 6.74 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "Gabapentin was dose-escalated from 300 mg/d to 1." | 6.71 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 6.71 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "Gabapentin was administered orally in gradually increasing doses up to a maximum of 2,400 mg/day." | 6.69 | Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Parker, F, 1998) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 6.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Gabapentin has been successfully used for the treatment of multiple neuropathic pain syndromes such as diabetic neuropathy and postherpetic neuralgia." | 6.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Gabapentin has become popular as a first-line treatment for neuropathic pain because of its efficacy as an antineuropathic agent and relatively benign side-effect profile." | 6.43 | The mechanism of action of gabapentin in neuropathic pain. ( Baillie, JK; Power, I, 2006) |
| "Neuropathic pain is a common and potentially treatable cause of considerable lifelong morbidity." | 6.43 | The mechanism of action of gabapentin in neuropathic pain. ( Baillie, JK; Power, I, 2006) |
| "Like gabapentin, pregabalin was predominantly excreted unchanged in the urine (> or = 98%)." | 6.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| " Unlike gabapentin, pregabalin was well absorbed (> 90%), and its absorption was dose independent." | 6.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| " Dosed at 50 to 200 mg TID, pregabalin was superior to placebo in relieving pain and improving sleep and health-related quality of life in patients with diabetic peripheral neuropathy and postherpetic neuralgia (P < 0." | 6.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| " The improved pharmacokinetic profile of pregabalin relative to gabapentin is manifested in linear and dose-independent absorption and a narrow therapeutic dosing range." | 6.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Pain is one of the most common reasons for seeking medical attention, and neuropathic pain is among the most common types of pain." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Despite its prevalence, neuropathic pain is often underrecognized and inadequately treated." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "It relieved symptoms of allodynia, burning pain, shooting pain, and hyperesthesia." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin has antihyperalgesic and antiallodynic properties but does not have significant actions as an anti-nociceptive agent." | 6.42 | Gabapentin in the treatment of neuropathic pain. ( Bennett, MI; Simpson, KH, 2004) |
| "Gabapentin is a novel anticonvulsant that may have a unique effect on voltage-dependent Ca2+ channel currents at postsynaptic dorsal horn neurons." | 6.41 | Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000) |
| "Gabapentin has been shown to be efficacious in numerous smaller clinical studies, case reports, and chart reviews in a variety of neuropathic pain syndromes." | 6.41 | Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000) |
| " The most common adverse reactions (incidence ≥ 20%) with single-agent use are fatigue, nausea, and anorexia." | 5.39 | Pemetrexed-induced cellulitis: a rare toxicity in non-small cell lung cancer treatment. ( Katsenos, S; Panagou, C; Psara, A, 2013) |
| "Pregabalin is one of the first-line treatments for painful diabetic peripheral neuropathy in many countries, and we have administered it to relieve the neurotoxicity associated with adverse effects of VCR in a DLBCL patient treated with the R-CHOP regimen." | 5.38 | [A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma]. ( Hosokawa, A; Ito, T; Kiba, T; Kido, M; Kimura, A; Kozawa, K; Nakashima, T; Niimi, H; Ogawa, Y; Okada, Y; Okikawa, Y; Saito, A; Shintani, H; Taniguchi, T; Taniyama, K, 2012) |
| "Paclitaxel can cause an acute pain syndrome (P-APS), considered to be an acute form of neuropathy and chronic chemotherapy-induced peripheral neuropathy (CIPN)." | 5.22 | Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial. ( Atherton, PJ; Lafky, J; Loprinzi, CL; Pachman, DR; Ruddy, KJ; Seisler, D; Shinde, SS; Soori, G, 2016) |
| " Our goal was to compare the effects of gabapentin and pregabalin on improving sleep quality and depression among hemodialysis patients with PPN." | 5.17 | Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. ( Atalay, H; Biyik, Z; Gaipov, A; Guney, F; Solak, Y; Turk, S, 2013) |
| "To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)." | 5.14 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 5.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-imipramine significantly decreased the total pain score and daily paroxysmal pain episodes." | 5.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects." | 5.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| " Gabapentin (GBP) is effective in painful diabetic neuropathy and postherpetic neuralgia and its effectiveness on painful HIV-SN has been reported anecdotally." | 5.11 | A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. ( Arendt, G; Braun, JS; Hahn, K; Husstedt, IW; Maschke, M; Schielke, E; Straube, ME; von Giesen, HJ, 2004) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 5.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "This study evaluated the effectiveness of gabapentin to treat cancer-related neuropathic pain." | 5.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "We conclude that gabapentin is an effective treatment for cancer-related neuropathic pain." | 5.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "To evaluate the effects of gabapentin on pain scores and opiate use." | 5.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| " A significant decrease in pain scores with gabapentin was seen in the neuropathic pain group (paired t-test, p < ." | 5.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| "Gabapentin may be a useful adjunct for treating neuropathic pain with a minimum of side effects." | 5.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| "A large case series of patients with centrally mediated pain, peripherally mediated pain, migraine, and tremor were treated in an open-label study with gabapentin (maximum of 2,700 mg/day)." | 5.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "Gabapentin offers an effective, safe alternative therapy or co-therapy for the listed painful conditions and tremor; it does not affect the metabolism of other medications and is well tolerated." | 5.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Recent studies showed effectiveness of gabapentin in improving the pain control in patients with neuropathic cancer pain, already treated with opiates." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Given the significant benefits of gabapentin and the combination of gabapentin with opioids for the treatment of neuropathic pain, randomized clinical trials are needed to establish the role of these analgesic regimens for the treatment of neuropathic cancer pain." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| " Multiple multicentre randomised controlled trials have shown clear efficacy of gabapentin and pregabalin for postherpetic neuralgia and painful diabetic neuropathy." | 4.84 | Antiepileptic drugs in the treatment of neuropathic pain. ( Eisenberg, E; Krivoy, N; River, Y; Shifrin, A, 2007) |
| " Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Randomized controlled studies of gabapentin for neuropathic pain were identified through a search of PubMed and MEDLINE from 1966 to the present using the search terms gabapentin, randomized, placebo, and pain." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "At doses of 1800 to 3600 mg/d, gabapentin was effective and well tolerated in the treatment of adults with neuropathic pain." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "This paper reviews the pharmacology and clinical effectiveness of gabapentin in the treatment of neuropathic pain." | 4.82 | Gabapentin in the treatment of neuropathic pain. ( Bennett, MI; Simpson, KH, 2004) |
| "To review pregabalin's pharmacology, pharmacokinetics, efficacy, and adverse effects in the treatment of neuropathic pain, epilepsy, and anxiety." | 4.82 | Pregabalin: a new neuromodulator with broad therapeutic indications. ( McAuley, JW; Shneker, BF, 2005) |
| " Key terms were anxiety, diabetic neuropathy, epilepsy, neuropathic pain, postherpetic neuralgia, pregabalin, and seizures." | 4.82 | Pregabalin: a new neuromodulator with broad therapeutic indications. ( McAuley, JW; Shneker, BF, 2005) |
| " The search terms included pregabalin, PD144723, CI-1008, gabapentin, and neuropathic pain." | 4.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "In preclinical studies, pregabalin, a structural congener of gabapentin, exhibited antinociceptive activity in animal models of neuropathic and inflammatory pain." | 4.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "This article reviews the available information on pregabalin, a new anticonvulsant for peripheral neuropathic pain." | 4.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "Muscle cramps associated with PNH respond well to symptomatic treatment, particularly with carbamazepine and gabapentin." | 3.83 | Therapeutic Implications of Peripheral Nerve Hyperexcitability in Muscle Cramping: A Retrospective Review. ( Hobson-Webb, LD; Hurst, RL, 2016) |
| "Thirteen patients with metastatic colorectal cancer who suffered from oxaliplatin-induced sensory neuropathy were evaluated to determine the neuropathy Grade before and after the administration of pregabalin." | 3.79 | [Promising effects of pregabalin in the treatment of oxaliplatin-induced sensory neuropathy in patients with colorectal carcinoma]. ( Hasegawa, T; Hirakawa, K; Hirakawa, T; Inoue, T; Maeda, K; Nagahara, H; Noda, E; Shibutani, M, 2013) |
| "The involvement of voltage-dependent calcium channels and reactive oxygen species in the pathophysiology of neuropathic pain might justify the preventative administration of antioxidant enzymes, at low doses, in combination with gabapentin (GaP) to maximize its analgesic effect in an experimental model of neuropathic pain in rats." | 3.79 | Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model. ( Arcos, M; Barrios, C; Montes, F; Palanca, JM, 2013) |
| "The effect of the cyclooxygenase-2 (COX-2) inhibitor etodolac on the mechanical allodynia induced by paclitaxel was investigated in mice and compared with the effects of the nonselective COX inhibitors indomethacin and diclofenac, the selective COX-2 inhibitor celecoxib, the calcium channel α(2)δ subunit inhibitor pregabalin, the sodium channel blocker mexiletine, and the serotonin-norepinephrine reuptake inhibitor duloxetine." | 3.78 | Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. ( Banno, K; Inoue, N; Ito, S; Kotera, T; Kyoi, T; Nakamura, A; Nogawa, M; Sasagawa, T; Tajima, K; Takahashi, Y; Ueda, M; Yamashita, Y, 2012) |
| "When performing R-CHOP(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)for diffuse large B-cell lymphoma(DLBCL), neurotoxicity of vincristine(VCR)is the serious dose-limiting factor." | 3.78 | [A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma]. ( Hosokawa, A; Ito, T; Kiba, T; Kido, M; Kimura, A; Kozawa, K; Nakashima, T; Niimi, H; Ogawa, Y; Okada, Y; Okikawa, Y; Saito, A; Shintani, H; Taniguchi, T; Taniyama, K, 2012) |
| "Numerous controlled clinical trials have demonstrated the safety and efficacy of pregabalin in the treatment of neuropathic pain." | 3.77 | Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. ( Anastassiou, E; Iatrou, CA; Lyras, L; Plesia, E; Stamatiou, G; Vadalouca, A; Vafiadou, M; Vlaikidis, N, 2011) |
| "This was a non-interventional, multicentre study in which pregabalin was administered for 8 weeks, at the therapeutic dosages of 150-600 mg/day, to patients with a diagnosis of neuropathic pain." | 3.77 | Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. ( Anastassiou, E; Iatrou, CA; Lyras, L; Plesia, E; Stamatiou, G; Vadalouca, A; Vafiadou, M; Vlaikidis, N, 2011) |
| "Significant reductions in pain and pain-related sleep interference, combined with reductions in feelings of anxiety and depression, suggest that pregabalin under real-world conditions improves the overall health and well-being of patients with neuropathic pain." | 3.77 | Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. ( Anastassiou, E; Iatrou, CA; Lyras, L; Plesia, E; Stamatiou, G; Vadalouca, A; Vafiadou, M; Vlaikidis, N, 2011) |
| "To determine the utility of substitution of pregabalin (PGB) for gabapentin (GBP) therapy in the relief of neuropathic pain (NeP) in patients with peripheral neuropathy (PN)." | 3.76 | Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. ( Toth, C, 2010) |
| "Peripherally administered pregabalin attenuates mechanical, cold, and heat allodynia in a rat model of neuropathic pain." | 3.76 | Attenuation of neuropathy-induced allodynia following intraplantar injection of pregabalin. ( Chang, HW; Hong, SH; Joo, HS; Lee, JY; Lee, Y; Moon, DE; Park, HJ, 2010) |
| "Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy." | 3.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain." | 3.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "Gabapentin is used in analgesic treatment of neuropathic pain, and large interindividual variation has been observed in the pharmacokinetics (PK) of the drug." | 3.75 | A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling. ( Carlsson, KC; Eriksen, HO; Hoem, NO; Karlsson, MO; Moberg, ER; van de Schootbrugge, M, 2009) |
| "We compared the inhibitory action of gabapentin, which is used to treat neuropathic pain, on mechanical allodynia induced by chemotherapeutic agents, paclitaxel, oxaliplatin, and vincristine, in mice." | 3.75 | Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit. ( Andoh, T; Fujita, M; Gauchan, P; Ikeda, K; Kato, A; Kuraishi, Y; Sasaki, A, 2009) |
| "The effects of treatment with the anti-convulsant agents, lamotrigine and riluzole were compared with gabapentin in a rat experimental model of neuropathic pain." | 3.74 | A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2007) |
| "We have previously demonstrated that gabapentin supraspinally activates the descending noradrenergic system to ameliorate pain hypersensitivity in mice with partial nerve ligation." | 3.74 | Gabapentin produces PKA-dependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice. ( Ono, H; Takasu, K; Tanabe, M, 2008) |
| " In the current study, we evaluated the behavioral effects of two standard drugs used clinically for neuropathic pain, the anticonvulsant gabapentin and antidepressant imipramine, in rats at different times after peripheral nerve injury." | 3.73 | The effect of antinociceptive drugs tested at different times after nerve injury in rats. ( Borsook, D; Hama, AT, 2005) |
| " In this study, we tested the hypothesis that removal of GABAergic and glycinergic inhibitory inputs attenuates the effect of morphine on dorsal horn projection neurons and the reduced spinal GABAergic tone contributes to attenuated morphine effect in neuropathic pain." | 3.73 | Effect of morphine on deep dorsal horn projection neurons depends on spinal GABAergic and glycinergic tone: implications for reduced opioid effect in neuropathic pain. ( Chen, SR; Chen, YP; Pan, HL, 2005) |
| "GABA and glycine are inhibitory neurotransmitters used by many neurons in the spinal dorsal horn, and intrathecal administration of GABA(A) and glycine receptor antagonists produces behavioural signs of allodynia, suggesting that these transmitters have an important role in spinal pain mechanisms." | 3.72 | Selective loss of spinal GABAergic or glycinergic neurons is not necessary for development of thermal hyperalgesia in the chronic constriction injury model of neuropathic pain. ( Hughes, DI; Maxwell, DJ; Polgár, E; Puskár, Z; Riddell, JS; Todd, AJ, 2003) |
| " When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%)." | 3.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "This study investigated the anti-allodynic and anti-oedematogenic effects of the hexanic extract, lignan-rich fraction and purified lignans from a plant used in the traditional medicine, Phyllanthus amarus, in the inflammatory and neuropathic models of nociception." | 3.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "We report a case of neutropenia occurring in a patient receiving gabapentin for neuropathic pain." | 3.72 | Neutropenia occurring after starting gabapentin for neuropathic pain. ( Derbyshire, E; Martin, D, 2004) |
| "The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain." | 3.71 | Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002) |
| "This study tests the hypothesis that loss of spinal activity of gamma-aminobutyric acid (GABA) contributes to the allodynia and hyperalgesia observed after peripheral nerve injury." | 3.71 | Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. ( Malan, TP; Mata, HP; Porreca, F, 2002) |
| "These results suggest a participation of autoimmunity in the pathogenesis of some cases of sporadic cerebellar cortical atrophy and the involvement of the cerebellar gamma-aminobutyric acid-ergic system in the pathogenesis of this disease." | 3.69 | Autoantibodies to glutamate decarboxylase in a patient with cerebellar cortical atrophy, peripheral neuropathy, and slow eye movements. ( Aguera, M; Belin, MF; Honnorat, J; Thivolet, C; Trouillas, P, 1995) |
| "Experimental studies indicate that the effects of spinal cord stimulation (SCS) on 'hypersymptoms' in neuropathic pain conditions may at least partly be mediated via GABAergic and adenosine-dependent mechanisms." | 3.69 | Modulation of spinal pain mechanisms by spinal cord stimulation and the potential role of adjuvant pharmacotherapy. ( Cui, JG; Linderoth, B; Meyerson, BA; O'Connor, WT; Segerdahl, M; Sollevi, A; Stiller, CO; Yakhnitsa, V, 1997) |
| "Paclitaxel can cause an acute pain syndrome (P-APS), considered to be an acute form of neuropathy and chronic chemotherapy-induced peripheral neuropathy (CIPN)." | 2.82 | Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial. ( Atherton, PJ; Lafky, J; Loprinzi, CL; Pachman, DR; Ruddy, KJ; Seisler, D; Shinde, SS; Soori, G, 2016) |
| " Discontinuation because of adverse events was significantly greater in the duloxetine (19." | 2.79 | Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain. ( Irving, G; Malcolm, S; Raskin, J; Risser, RC; Tanenberg, RJ, 2014) |
| "Duloxetine, pregabalin and duloxetine plus gabapentin were generally safe and tolerable for the treatment of DPNP." | 2.79 | Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain. ( Irving, G; Malcolm, S; Raskin, J; Risser, RC; Tanenberg, RJ, 2014) |
| " The aim of this study was to see whether low-dose gabapentin is effective in treating cancer-related neuropathic pain when combined with low-dose imipramine." | 2.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects." | 2.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Painful neuropathic conditions of cancer pain often show little response to nonopioid and opioid analgesics but may be eased by antidepressants and anticonvulsants." | 2.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 2.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| " Patients in group B who were receiving gabapentin continued this treatment up to a maximum daily dosage of 2400 mg during the observation period." | 2.74 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "Multimodal pain is comprised of nociceptive/inflammatory and neuropathic components." | 2.74 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "Chronic neuropathic pain was associated with motor cortex disinhibition, suggesting impaired GABAergic neurotransmission related to some aspects of pain or to underlying sensory or motor disturbances." | 2.72 | Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain. ( Drouot, X; Keravel, Y; Lefaucheur, JP; Ménard-Lefaucheur, I; Nguyen, JP, 2006) |
| "Gabapentin was dose-escalated from 300 mg/d to 1." | 2.71 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 2.71 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "Gabapentin was administered orally in gradually increasing doses up to a maximum of 2,400 mg/day." | 2.69 | Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Parker, F, 1998) |
| " Rodent models of CIPN have been developed using a range of dosing regimens to reproduce pain-like behaviours akin to patient-reported symptoms." | 2.53 | Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics. ( Duggett, NA; Flatters, SJL; Hopkins, HL, 2016) |
| " We present an overview of dosing regimens to produce CIPN models and their phenotype of pain-like behaviours." | 2.53 | Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics. ( Duggett, NA; Flatters, SJL; Hopkins, HL, 2016) |
| "The review outlines the latest description of the most-relevant rodent models of CIPN enabling comparison between chemotherapeutics, dosing regimen, rodent strain, and sex." | 2.53 | Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics. ( Duggett, NA; Flatters, SJL; Hopkins, HL, 2016) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 2.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Gabapentin has been successfully used for the treatment of multiple neuropathic pain syndromes such as diabetic neuropathy and postherpetic neuralgia." | 2.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Gabapentin has become popular as a first-line treatment for neuropathic pain because of its efficacy as an antineuropathic agent and relatively benign side-effect profile." | 2.43 | The mechanism of action of gabapentin in neuropathic pain. ( Baillie, JK; Power, I, 2006) |
| "Neuropathic pain is a common and potentially treatable cause of considerable lifelong morbidity." | 2.43 | The mechanism of action of gabapentin in neuropathic pain. ( Baillie, JK; Power, I, 2006) |
| "Like gabapentin, pregabalin was predominantly excreted unchanged in the urine (> or = 98%)." | 2.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| " Unlike gabapentin, pregabalin was well absorbed (> 90%), and its absorption was dose independent." | 2.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| " Dosed at 50 to 200 mg TID, pregabalin was superior to placebo in relieving pain and improving sleep and health-related quality of life in patients with diabetic peripheral neuropathy and postherpetic neuralgia (P < 0." | 2.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| " The improved pharmacokinetic profile of pregabalin relative to gabapentin is manifested in linear and dose-independent absorption and a narrow therapeutic dosing range." | 2.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Pain is one of the most common reasons for seeking medical attention, and neuropathic pain is among the most common types of pain." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Despite its prevalence, neuropathic pain is often underrecognized and inadequately treated." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "It relieved symptoms of allodynia, burning pain, shooting pain, and hyperesthesia." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin has antihyperalgesic and antiallodynic properties but does not have significant actions as an anti-nociceptive agent." | 2.42 | Gabapentin in the treatment of neuropathic pain. ( Bennett, MI; Simpson, KH, 2004) |
| "Gabapentin is a novel anticonvulsant that may have a unique effect on voltage-dependent Ca2+ channel currents at postsynaptic dorsal horn neurons." | 2.41 | Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000) |
| "Gabapentin has been shown to be efficacious in numerous smaller clinical studies, case reports, and chart reviews in a variety of neuropathic pain syndromes." | 2.41 | Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000) |
| "The treatment with gabapentin or LLLT significantly decreased the raised level in total cholesterol in DNP but could not decrease the elevated level of triglycerides, while LDL cholesterol decreased significantly in DNP treated with gabapentin but not affected by LLLT." | 1.48 | Efficiencies of Low-Level Laser Therapy (LLLT) and Gabapentin in the Management of Peripheral Neuropathy: Diabetic Neuropathy. ( Abdel-Wahhab, KG; Daoud, EM; El Gendy, A; Mannaa, FA; Mourad, HH; Saber, MM, 2018) |
| " In this study, pregabalin was shown to positively impact sensory neuropathy resulting from oxaliplatin treatment and to enable the long-term use of oxaliplatin-based chemotherapy." | 1.39 | [Promising effects of pregabalin in the treatment of oxaliplatin-induced sensory neuropathy in patients with colorectal carcinoma]. ( Hasegawa, T; Hirakawa, K; Hirakawa, T; Inoue, T; Maeda, K; Nagahara, H; Noda, E; Shibutani, M, 2013) |
| "Thirteen patients with metastatic colorectal cancer who suffered from oxaliplatin-induced sensory neuropathy were evaluated to determine the neuropathy Grade before and after the administration of pregabalin." | 1.39 | [Promising effects of pregabalin in the treatment of oxaliplatin-induced sensory neuropathy in patients with colorectal carcinoma]. ( Hasegawa, T; Hirakawa, K; Hirakawa, T; Inoue, T; Maeda, K; Nagahara, H; Noda, E; Shibutani, M, 2013) |
| " In 28-37% of patients, pregabalin was associated with adverse events, with drowsiness and dizziness being frequently observed." | 1.39 | [Efficacy and safety of pregabalin for oxaliplatin- and paclitaxel-induced peripheral neuropathy]. ( Itabashi, T; Kashiwaba, M; Kudo, K; Nihei, S; Sato, J; Takahashi, K, 2013) |
| "Neuropathic pain is a chronic neurodegenerative disease." | 1.39 | Antinociceptive effect of Butea monosperma on vincristine-induced neuropathic pain model in rats. ( Krishnan, UM; Muthuraman, A; Shanmugam, P; Singh, N; Thiagarajan, VR, 2013) |
| " The most common adverse reactions (incidence ≥ 20%) with single-agent use are fatigue, nausea, and anorexia." | 1.39 | Pemetrexed-induced cellulitis: a rare toxicity in non-small cell lung cancer treatment. ( Katsenos, S; Panagou, C; Psara, A, 2013) |
| "Pregabalin is one of the first-line treatments for painful diabetic peripheral neuropathy in many countries, and we have administered it to relieve the neurotoxicity associated with adverse effects of VCR in a DLBCL patient treated with the R-CHOP regimen." | 1.38 | [A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma]. ( Hosokawa, A; Ito, T; Kiba, T; Kido, M; Kimura, A; Kozawa, K; Nakashima, T; Niimi, H; Ogawa, Y; Okada, Y; Okikawa, Y; Saito, A; Shintani, H; Taniguchi, T; Taniyama, K, 2012) |
| "Many drugs approved for neuropathic pain engage spinal noradrenergic and cholinergic systems for analgesia." | 1.37 | A tropomyosine receptor kinase inhibitor blocks spinal neuroplasticity essential for the anti-hypersensitivity effects of gabapentin and clonidine in rats with peripheral nerve injury. ( Eisenach, JC; Hayashida, K, 2011) |
| "We describe a 23-year-old woman with neuritis ossificans involving the tibial, common peroneal and lateral sural nerves." | 1.37 | Neuritis ossificans of the tibial, common peroneal and lateral sural cutaneous nerves. ( Eisen, R; Katz, LD; Lindskog, D, 2011) |
| "The cold allodynia was assessed by the tail immersion test (i." | 1.36 | Spinal GABA receptors mediate the suppressive effect of electroacupuncture on cold allodynia in rats. ( Go, DH; Han, JB; Kim, SK; Min, BI; Park, JH; Sun, B, 2010) |
| "Neuropathic pain is a major health issue and is frequently accompanied by allodynia (painful sensations in response to normally non-painful stimulations), and unpleasant paresthesia/dysesthesia, pointing to alterations in sensory pathways normally dedicated to the processing of non-nociceptive information." | 1.36 | Upregulation of the GABA transporter GAT-1 in the gracile nucleus in the spared nerve injury model of neuropathic pain. ( Bebber, D; Decosterd, I; Gosselin, RD, 2010) |
| " Single, parenteral dosing of donepezil (1, 1." | 1.36 | Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies. ( Andersen, LM; Bjerrum, OJ; Folkesson, A; Honoré, PH; Kristensen, P, 2010) |
| " Bioavailability was included in the models as a function of dose by using a hyperbolic function derived from data previously reported in the literature." | 1.35 | A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling. ( Carlsson, KC; Eriksen, HO; Hoem, NO; Karlsson, MO; Moberg, ER; van de Schootbrugge, M, 2009) |
| " Steady-state serum concentrations of gabapentin, distributed over a dosage interval, were obtained from 16 adult patients." | 1.35 | A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling. ( Carlsson, KC; Eriksen, HO; Hoem, NO; Karlsson, MO; Moberg, ER; van de Schootbrugge, M, 2009) |
| "Gabapentin has been used effectively for neuropathic pain with mild side effects." | 1.35 | Gabapentin and sexual dysfunction: report of two cases. ( Dalal, A; Zhou, L, 2008) |
| " A flexible dosing approach appears appropriate to ensure patient compliance and treatment success." | 1.34 | Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. ( Freynhagen, R; Grond, S; Hagebeuker, A; Junker, U; Konrad, C; Schmelz, M; Schüpfer, G; Von Giesen, HJ; Wagner, KJ; Ziegler, D, 2007) |
| "Six children with cerebral palsy are presented who developed neuropathic pain following multilevel orthopedic surgery." | 1.33 | Neuropathic pain following multilevel surgery in children with cerebral palsy: a case series and review. ( Lauder, GR; White, MC, 2005) |
| "Gabapentin (GBP) has been shown to be effective in animal models of neuropathic pain as well as in chronic pain patients." | 1.33 | Effects of gabapentin on spontaneous discharges and subthreshold membrane potential oscillation of type A neurons in injured DRG. ( Duan, JH; Hu, SJ; Xing, JL; Yang, RH, 2005) |
| "Neuropathic pain is a clinical manifestation characterized by the presence of spontaneous pain, allodynia and hyperalgesia." | 1.33 | Development and expression of neuropathic pain in CB1 knockout mice. ( Castañé, A; Célérier, E; Ledent, C; Maldonado, R; Martín, M; Parmentier, M; Valverde, O, 2006) |
| "The development of mechanical and thermal allodynia, and thermal hyperalgesia was evaluated by using the von Frey filaments, cold-plate and plantar tests, respectively." | 1.33 | Development and expression of neuropathic pain in CB1 knockout mice. ( Castañé, A; Célérier, E; Ledent, C; Maldonado, R; Martín, M; Parmentier, M; Valverde, O, 2006) |
| "Mechanical allodynia was maximal by 1 week and persisted at blunted levels for at least 18 weeks after injury." | 1.33 | Spinal nerve ligation does not alter the expression or function of GABA(B) receptors in spinal cord and dorsal root ganglia of the rat. ( Bettler, B; Engle, MP; Gassman, M; Hammond, DL; Sykes, KT, 2006) |
| "Paclitaxel (Taxol) is a widely used chemotherapeutic agent in the treatment of several tumors." | 1.33 | Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. ( Hald, A; Inoue, M; Matsumoto, M; Ueda, H; Xie, W, 2006) |
| " Hill slope coefficients for the tested anticonvulsants indicate that the dose-response curve was less steep for gabapentin than for phenytoin, carbamazepine and ethosuximide." | 1.32 | Potent analgesic effects of anticonvulsants on peripheral thermal nociception in rats. ( Jevtovic-Todorovic, V; Rastogi, AJ; Todorovic, SM, 2003) |
| "Tactile allodynia was quantitated using the threshold to withdrawal of the hind paw on probing with von Frey filaments." | 1.31 | Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. ( Malan, TP; Mata, HP; Porreca, F, 2002) |
| "Isoguvacine and baclofen each reversed tactile allodynia and thermal hyperalgesia produced by spinal nerve ligation." | 1.31 | Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. ( Malan, TP; Mata, HP; Porreca, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.20) | 18.7374 |
| 1990's | 13 (7.83) | 18.2507 |
| 2000's | 96 (57.83) | 29.6817 |
| 2010's | 55 (33.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, H | 1 |
| Liu, HZ | 1 |
| Zhang, WW | 1 |
| Matsuda, M | 1 |
| Lv, N | 1 |
| Chen, G | 1 |
| Xu, ZZ | 1 |
| Zhang, YQ | 1 |
| Abdel-Wahhab, KG | 1 |
| Daoud, EM | 1 |
| El Gendy, A | 1 |
| Mourad, HH | 1 |
| Mannaa, FA | 1 |
| Saber, MM | 1 |
| Magnowska, M | 1 |
| Iżycka, N | 1 |
| Kapoła-Czyż, J | 1 |
| Romała, A | 1 |
| Lorek, J | 1 |
| Spaczyński, M | 1 |
| Nowak-Markwitz, E | 1 |
| Kanbayashi, Y | 1 |
| Hosokawa, T | 1 |
| Kitawaki, J | 1 |
| Taguchi, T | 1 |
| Atalay, H | 2 |
| Solak, Y | 2 |
| Biyik, Z | 2 |
| Gaipov, A | 2 |
| Guney, F | 2 |
| Turk, S | 2 |
| Tesfaye, S | 1 |
| Boulton, AJ | 1 |
| Dickenson, AH | 2 |
| Nagahara, H | 1 |
| Noda, E | 1 |
| Maeda, K | 1 |
| Inoue, T | 1 |
| Hirakawa, T | 1 |
| Hasegawa, T | 1 |
| Shibutani, M | 1 |
| Hirakawa, K | 1 |
| Nihei, S | 1 |
| Sato, J | 1 |
| Kashiwaba, M | 1 |
| Itabashi, T | 1 |
| Kudo, K | 1 |
| Takahashi, K | 1 |
| Aoki, M | 1 |
| Kurauchi, Y | 1 |
| Mori, A | 1 |
| Nakahara, T | 1 |
| Sakamoto, K | 1 |
| Ishii, K | 1 |
| Hershman, DL | 1 |
| Lacchetti, C | 1 |
| Dworkin, RH | 1 |
| Lavoie Smith, EM | 1 |
| Bleeker, J | 1 |
| Cavaletti, G | 1 |
| Chauhan, C | 1 |
| Gavin, P | 1 |
| Lavino, A | 1 |
| Lustberg, MB | 1 |
| Paice, J | 1 |
| Schneider, B | 1 |
| Smith, ML | 1 |
| Smith, T | 1 |
| Terstriep, S | 1 |
| Wagner-Johnston, N | 1 |
| Bak, K | 1 |
| Loprinzi, CL | 3 |
| Irving, G | 1 |
| Tanenberg, RJ | 1 |
| Raskin, J | 1 |
| Risser, RC | 1 |
| Malcolm, S | 1 |
| Shinde, SS | 1 |
| Seisler, D | 1 |
| Soori, G | 1 |
| Atherton, PJ | 1 |
| Pachman, DR | 1 |
| Lafky, J | 1 |
| Ruddy, KJ | 1 |
| Bonnet, U | 1 |
| Ossowski, A | 1 |
| Schubert, M | 1 |
| Gall, H | 1 |
| Steinkamp, I | 1 |
| Richter, LE | 1 |
| Khalil-Boutros, Y | 1 |
| Nefedev, A | 1 |
| Kuhlmann, R | 1 |
| Hopkins, HL | 1 |
| Duggett, NA | 1 |
| Flatters, SJL | 1 |
| Hurst, RL | 1 |
| Hobson-Webb, LD | 1 |
| Ward, RE | 1 |
| Veerula, VL | 1 |
| Ezra, N | 1 |
| Travers, JB | 1 |
| Mousdicas, N | 1 |
| Pongcharoen, P | 1 |
| Fleischer, AB | 1 |
| Şavk, E | 1 |
| Young, T | 1 |
| Wittenauer, S | 1 |
| Parker, R | 1 |
| Vincler, M | 1 |
| Polgár, E | 2 |
| Todd, AJ | 2 |
| Hayashida, K | 2 |
| Eisenach, JC | 2 |
| Ho, TW | 1 |
| Backonja, M | 2 |
| Ma, J | 1 |
| Leibensperger, H | 1 |
| Froman, S | 1 |
| Polydefkis, M | 1 |
| Pigatto, PD | 1 |
| Guzzi, G | 1 |
| Carlsson, KC | 1 |
| van de Schootbrugge, M | 1 |
| Eriksen, HO | 1 |
| Moberg, ER | 1 |
| Karlsson, MO | 1 |
| Hoem, NO | 1 |
| Linam, WM | 1 |
| Wesselkamper, K | 1 |
| Gerber, MA | 1 |
| Prommer, EE | 1 |
| Chiechio, S | 1 |
| Zammataro, M | 1 |
| Caraci, F | 1 |
| Rampello, L | 1 |
| Copani, A | 1 |
| Sabato, AF | 2 |
| Nicoletti, F | 1 |
| Gustafsson, H | 1 |
| Sandin, J | 1 |
| Eker, HE | 1 |
| Cok, OY | 1 |
| Aribogan, A | 1 |
| Gauchan, P | 1 |
| Andoh, T | 2 |
| Ikeda, K | 1 |
| Fujita, M | 1 |
| Sasaki, A | 2 |
| Kato, A | 1 |
| Kuraishi, Y | 2 |
| Omori, Y | 1 |
| Kagaya, K | 1 |
| Enomoto, R | 1 |
| Nojima, H | 1 |
| Takahata, H | 1 |
| Mao, YF | 1 |
| Liu, XR | 1 |
| Liao, XZ | 1 |
| Lv, YH | 1 |
| Xu, H | 1 |
| Deng, XM | 1 |
| Yan, SK | 1 |
| Xiong, YC | 1 |
| Zhang, WD | 1 |
| Domínguez Suárez, E | 1 |
| Pardo-Sobrino, F | 1 |
| Pensado Castiñeiras, A | 1 |
| Cores Viqueira, MJ | 1 |
| López-Rouco, M | 1 |
| Gatti, A | 1 |
| Carucci, A | 1 |
| Bertini, L | 1 |
| Mammucari, M | 1 |
| Occhioni, R | 1 |
| Devor, M | 1 |
| Halum, SL | 1 |
| Sycamore, DL | 1 |
| McRae, BR | 1 |
| Okabe, T | 1 |
| Sato, C | 1 |
| Matsumoto, K | 1 |
| Ozawa, H | 1 |
| Sakamoto, A | 1 |
| Buvanendran, A | 2 |
| Kroin, JS | 2 |
| Della Valle, CJ | 1 |
| Kari, M | 1 |
| Moric, M | 1 |
| Tuman, KJ | 2 |
| Tanabe, M | 2 |
| Takasu, K | 2 |
| Ono, H | 2 |
| Toth, C | 1 |
| Park, JH | 2 |
| Han, JB | 1 |
| Kim, SK | 1 |
| Go, DH | 1 |
| Sun, B | 1 |
| Min, BI | 1 |
| Kopsky, DJ | 1 |
| Keppel Hesselink, JM | 1 |
| Arai, YC | 1 |
| Matsubara, T | 1 |
| Shimo, K | 1 |
| Suetomi, K | 1 |
| Nishihara, M | 1 |
| Ushida, T | 1 |
| Kobayashi, K | 1 |
| Suzuki, C | 1 |
| Kinoshita, A | 1 |
| Kondo, M | 1 |
| Matsubara, S | 1 |
| Hayashi, R | 1 |
| Tohyama, Y | 1 |
| Nishida, K | 1 |
| Arakawa, M | 1 |
| Lampl, C | 1 |
| Schweiger, C | 1 |
| Haider, B | 1 |
| Lechner, A | 1 |
| Attal, N | 2 |
| Cruccu, G | 2 |
| Baron, R | 2 |
| Haanpää, M | 1 |
| Hansson, P | 1 |
| Jensen, TS | 1 |
| Nurmikko, T | 2 |
| Rashiq, S | 1 |
| Park, HJ | 1 |
| Joo, HS | 1 |
| Chang, HW | 1 |
| Lee, JY | 1 |
| Hong, SH | 1 |
| Lee, Y | 1 |
| Moon, DE | 2 |
| Kolosov, A | 1 |
| Goodchild, CS | 1 |
| Cooke, I | 1 |
| Bar Ad, V | 1 |
| Sirven, JI | 1 |
| Gosselin, RD | 1 |
| Bebber, D | 1 |
| Decosterd, I | 2 |
| Gemignani, F | 1 |
| Ferrari, G | 1 |
| Vitetta, F | 1 |
| Giovanelli, M | 1 |
| Macaluso, C | 1 |
| Marbini, A | 1 |
| Pérez, C | 1 |
| Navarro, A | 1 |
| Saldaña, MT | 1 |
| Masramón, X | 1 |
| Rejas, J | 3 |
| Finch, CK | 1 |
| Eason, J | 1 |
| Usery, JB | 1 |
| Folkesson, A | 1 |
| Honoré, PH | 1 |
| Andersen, LM | 1 |
| Kristensen, P | 1 |
| Bjerrum, OJ | 1 |
| Lee, DI | 1 |
| Lee, SC | 1 |
| Song, SO | 1 |
| Yoon, DM | 1 |
| Yoon, MH | 1 |
| Kim, HK | 1 |
| Lee, YW | 1 |
| Kim, C | 1 |
| Lee, PB | 1 |
| Anastassiou, E | 1 |
| Iatrou, CA | 1 |
| Vlaikidis, N | 1 |
| Vafiadou, M | 1 |
| Stamatiou, G | 1 |
| Plesia, E | 1 |
| Lyras, L | 1 |
| Vadalouca, A | 1 |
| Katz, LD | 1 |
| Lindskog, D | 1 |
| Eisen, R | 1 |
| Sicras-Mainar, A | 1 |
| Rejas-Gutiérrez, J | 1 |
| Navarro-Artieda, R | 1 |
| Planas-Comes, A | 1 |
| Janssen, SP | 1 |
| Gerard, S | 1 |
| Raijmakers, ME | 1 |
| Truin, M | 1 |
| Van Kleef, M | 1 |
| Joosten, EA | 1 |
| Thiagarajan, VR | 2 |
| Shanmugam, P | 2 |
| Krishnan, UM | 2 |
| Muthuraman, A | 2 |
| Singh, N | 1 |
| Hosseini-Zare, MS | 1 |
| Dashti-Khavidaki, S | 1 |
| Mahdavi-Mazdeh, M | 1 |
| Ahmadi, F | 1 |
| Akrami, S | 1 |
| Tan, IL | 1 |
| Polydefkis, MJ | 1 |
| Ebenezer, GJ | 1 |
| Hauer, P | 1 |
| McArthur, JC | 1 |
| Katsenos, S | 1 |
| Psara, A | 1 |
| Panagou, C | 1 |
| Ito, S | 1 |
| Tajima, K | 1 |
| Nogawa, M | 1 |
| Inoue, N | 1 |
| Kyoi, T | 1 |
| Takahashi, Y | 1 |
| Sasagawa, T | 1 |
| Nakamura, A | 1 |
| Kotera, T | 1 |
| Ueda, M | 1 |
| Yamashita, Y | 1 |
| Banno, K | 1 |
| Nakashima, T | 2 |
| Kiba, T | 2 |
| Ogawa, Y | 2 |
| Kimura, A | 1 |
| Kido, M | 1 |
| Okikawa, Y | 1 |
| Ito, T | 1 |
| Saito, A | 1 |
| Hosokawa, A | 2 |
| Shintani, H | 2 |
| Okada, Y | 2 |
| Taniguchi, T | 2 |
| Taniyama, K | 1 |
| Kozawa, K | 2 |
| Niimi, H | 1 |
| Gammaitoni, AR | 1 |
| Smugar, SS | 1 |
| Jensen, MP | 1 |
| Galer, BS | 1 |
| Bolognese, JA | 1 |
| Alon, A | 1 |
| Hewitt, DJ | 1 |
| Aurora, RN | 1 |
| Kristo, DA | 1 |
| Bista, SR | 1 |
| Rowley, JA | 1 |
| Zak, RS | 1 |
| Casey, KR | 1 |
| Lamm, CI | 1 |
| Tracy, SL | 1 |
| Rosenberg, RS | 1 |
| Kozma, CM | 1 |
| Benson, C | 1 |
| Slaton, TL | 1 |
| Kim, MS | 1 |
| Vorsanger, GJ | 1 |
| Shigeta, M | 1 |
| Gerlinger, I | 1 |
| Arcos, M | 1 |
| Palanca, JM | 1 |
| Montes, F | 1 |
| Barrios, C | 1 |
| Moore, KA | 2 |
| Kohno, T | 2 |
| Karchewski, LA | 1 |
| Scholz, J | 1 |
| Baba, H | 2 |
| Woolf, CJ | 3 |
| Surges, R | 1 |
| Feuerstein, TJ | 1 |
| Field, MJ | 3 |
| Gonzalez, MI | 1 |
| Tallarida, RJ | 1 |
| Singh, L | 1 |
| Bortalanza, LB | 1 |
| Ferreira, J | 1 |
| Hess, SC | 1 |
| Delle Monache, F | 1 |
| Yunes, RA | 1 |
| Calixto, JB | 2 |
| Glanzman, RL | 1 |
| Sarantopoulos, C | 1 |
| McCallum, B | 1 |
| Sapunar, D | 1 |
| Kwok, WM | 1 |
| Hogan, Q | 1 |
| Hughes, DI | 1 |
| Riddell, JS | 1 |
| Maxwell, DJ | 1 |
| Puskár, Z | 1 |
| Todorovic, SM | 1 |
| Rastogi, AJ | 1 |
| Jevtovic-Todorovic, V | 1 |
| SUZUKI, D | 1 |
| KUROTAKI, N | 1 |
| KAJINO, H | 1 |
| SATO, K | 1 |
| Kassuya, CA | 1 |
| Silvestre, AA | 1 |
| Rehder, VL | 1 |
| Ji, RR | 1 |
| Ataka, T | 1 |
| Wakai, A | 1 |
| Okamoto, M | 1 |
| Reyes-García, G | 2 |
| Medina-Santillán, R | 2 |
| Rocha-González, HI | 1 |
| Granados-Soto, V | 2 |
| Bennett, MI | 1 |
| Simpson, KH | 1 |
| Dost, R | 1 |
| Rostock, A | 1 |
| Rundfeldt, C | 1 |
| Yetimalar, Y | 1 |
| Gürgör, N | 1 |
| Başoğlu, M | 1 |
| Rotella, DP | 1 |
| Simjee, SU | 1 |
| Pleuvry, BJ | 1 |
| Coulthard, P | 1 |
| Ilag, VL | 1 |
| Allchorne, A | 1 |
| Dahl, JB | 1 |
| Mathiesen, O | 1 |
| Møiniche, S | 1 |
| Back, SK | 1 |
| Won, SY | 1 |
| Hong, SK | 1 |
| Na, HS | 1 |
| Hahn, K | 1 |
| Arendt, G | 1 |
| Braun, JS | 1 |
| von Giesen, HJ | 2 |
| Husstedt, IW | 1 |
| Maschke, M | 1 |
| Straube, ME | 1 |
| Schielke, E | 1 |
| Derbyshire, E | 1 |
| Martin, D | 1 |
| Caram-Salas, NL | 1 |
| Braune, S | 1 |
| Lauder, GR | 1 |
| White, MC | 1 |
| Yang, RH | 1 |
| Xing, JL | 1 |
| Duan, JH | 1 |
| Hu, SJ | 1 |
| Hama, AT | 1 |
| Borsook, D | 1 |
| Chen, YP | 1 |
| Chen, SR | 1 |
| Pan, HL | 1 |
| Cochran, E | 1 |
| Dani, K | 1 |
| Ramachandran, R | 1 |
| Capell, HA | 1 |
| Madhok, R | 1 |
| Castañé, A | 1 |
| Célérier, E | 1 |
| Martín, M | 1 |
| Ledent, C | 1 |
| Parmentier, M | 1 |
| Maldonado, R | 1 |
| Valverde, O | 1 |
| Gilron, I | 1 |
| Max, MB | 1 |
| Shneker, BF | 1 |
| McAuley, JW | 1 |
| Suzuki, R | 1 |
| Ross, JR | 1 |
| Goller, K | 1 |
| Hardy, J | 1 |
| Riley, J | 1 |
| Broadley, K | 1 |
| A'hern, R | 1 |
| Williams, J | 1 |
| Baillie, JK | 1 |
| Power, I | 1 |
| Engle, MP | 1 |
| Gassman, M | 1 |
| Sykes, KT | 1 |
| Bettler, B | 1 |
| Hammond, DL | 1 |
| Guay, DR | 1 |
| Gálvez, R | 1 |
| Marsal, C | 1 |
| Vidal, J | 1 |
| Ruiz, M | 2 |
| Matsumoto, M | 1 |
| Inoue, M | 1 |
| Hald, A | 1 |
| Xie, W | 1 |
| Ueda, H | 1 |
| Ribera, MV | 1 |
| Masrramón, X | 1 |
| Lefaucheur, JP | 1 |
| Drouot, X | 1 |
| Ménard-Lefaucheur, I | 1 |
| Keravel, Y | 1 |
| Nguyen, JP | 1 |
| Sonnett, TE | 1 |
| Setter, SM | 1 |
| Campbell, RK | 1 |
| Coderre, TJ | 2 |
| Kumar, N | 1 |
| Lefebvre, CD | 1 |
| Yu, JS | 1 |
| Mishriki, YY | 1 |
| Norman, P | 1 |
| Melrose, HL | 1 |
| Kinloch, RA | 1 |
| Cox, PJ | 1 |
| Collins, D | 1 |
| Williams, D | 1 |
| Yogeeswari, P | 1 |
| Ragavendran, JV | 1 |
| Sriram, D | 1 |
| Nageswari, Y | 1 |
| Kavya, R | 1 |
| Sreevatsan, N | 1 |
| Vanitha, K | 1 |
| Stables, J | 1 |
| Li, Z | 1 |
| Schwarz, JB | 1 |
| Wallace, JM | 1 |
| Eisenberg, E | 1 |
| River, Y | 1 |
| Shifrin, A | 1 |
| Krivoy, N | 1 |
| Rao, RD | 1 |
| Michalak, JC | 1 |
| Sloan, JA | 1 |
| Soori, GS | 1 |
| Nikcevich, DA | 1 |
| Warner, DO | 1 |
| Novotny, P | 1 |
| Kutteh, LA | 1 |
| Wong, GY | 1 |
| Whitlock, EL | 1 |
| Moradzadeh, A | 1 |
| Hunter, DA | 1 |
| Mackinnon, SE | 1 |
| Freynhagen, R | 1 |
| Grond, S | 1 |
| Schüpfer, G | 1 |
| Hagebeuker, A | 1 |
| Schmelz, M | 1 |
| Ziegler, D | 1 |
| Junker, U | 1 |
| Wagner, KJ | 1 |
| Konrad, C | 1 |
| Loosemore, MP | 1 |
| Bordeaux, JS | 1 |
| Bernhard, JD | 1 |
| Galluzzi, KE | 1 |
| Nymdelger, S | 1 |
| Nieber, K | 1 |
| Tanimoto-Mori, S | 1 |
| Nakazato-Imasato, E | 1 |
| Toide, K | 1 |
| Kita, Y | 1 |
| Dalal, A | 1 |
| Zhou, L | 1 |
| Millecamps, M | 1 |
| Benbouzid, M | 1 |
| Choucair-Jaafar, N | 1 |
| Yalcin, I | 1 |
| Waltisperger, E | 1 |
| Muller, A | 1 |
| Freund-Mercier, MJ | 1 |
| Barrot, M | 1 |
| Haslam, C | 1 |
| Beritić, T | 1 |
| Honnorat, J | 1 |
| Trouillas, P | 1 |
| Thivolet, C | 1 |
| Aguera, M | 1 |
| Belin, MF | 1 |
| Rosner, H | 1 |
| Rubin, L | 1 |
| Kestenbaum, A | 1 |
| Satoh, O | 1 |
| Omote, K | 1 |
| Cui, JG | 3 |
| Linderoth, B | 3 |
| Meyerson, BA | 3 |
| Rosenberg, JM | 1 |
| Harrell, C | 1 |
| Ristic, H | 1 |
| Werner, RA | 1 |
| de Rosayro, AM | 1 |
| O'Connor, WT | 2 |
| Ungerstedt, U | 1 |
| Newshan, G | 1 |
| McCaffery, M | 1 |
| Yakhnitsa, V | 1 |
| Sollevi, A | 1 |
| Segerdahl, M | 1 |
| Stiller, CO | 1 |
| Merren, MD | 1 |
| Brasseur, L | 1 |
| Parker, F | 1 |
| Chauvin, M | 1 |
| Bouhassira, D | 1 |
| de Oliveira, JO | 1 |
| Fortini, I | 1 |
| de Andrade, MP | 1 |
| Vadivelu, N | 1 |
| Berger, J | 1 |
| Mertens, P | 1 |
| Ghaemmaghami, C | 1 |
| Bert, L | 1 |
| Perret-Liaudet, A | 1 |
| Sindou, M | 1 |
| Renaud, B | 1 |
| Nicholson, B | 1 |
| Eaton, MJ | 1 |
| LaBuda, CJ | 1 |
| Fuchs, PN | 1 |
| Monhemius, R | 1 |
| Green, DL | 1 |
| Roberts, MH | 1 |
| Azami, J | 1 |
| Batoon, SB | 1 |
| Vela, AT | 1 |
| Dave, D | 1 |
| Wahid, Z | 1 |
| Conetta, R | 1 |
| Iakovou, C | 1 |
| Banzuela, M | 1 |
| Corradini, L | 1 |
| Briscini, L | 1 |
| Ongini, E | 1 |
| Bertorelli, R | 1 |
| Somers, DL | 1 |
| Clemente, FR | 1 |
| Malan, TP | 1 |
| Mata, HP | 1 |
| Porreca, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy[NCT04920097] | 240 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| The Benefits of Vitamin B Combination as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient: Randomized Clinical Trial[NCT04689971] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| Intravenous Lidocaine Infusion Versus Oral Duloxetine For The Prevention And Treatment Of Chemotherapy Induced Peripheral Neuropathy Among Breast Cancer Patients[NCT04732455] | 60 participants (Actual) | Interventional | 2021-01-15 | Completed | |||
| The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer[NCT04558034] | 14 participants (Actual) | Interventional | 2020-08-04 | Terminated (stopped due to Principal Investigator retired before study completed.) | |||
| Effect of Cryotherapy in Controlling Peripheral Neuropathy in Cancer Children[NCT04536207] | 60 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)[NCT04780854] | Phase 2 | 68 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)[NCT04299893] | Phase 2/Phase 3 | 42 participants (Anticipated) | Interventional | 2020-11-30 | Recruiting | ||
| Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study[NCT05798884] | 150 participants (Anticipated) | Interventional | 2023-05-31 | Not yet recruiting | |||
| An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain[NCT00385671] | Phase 4 | 407 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Prospective, Randomized Controlled Trial on Perioperative Pregabalin to Reduce Late-onset Complex Regional Pain Syndrome After Total Knee Arthroplasty[NCT00558753] | Phase 2 | 240 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Preemptive Analgesia With Amitryptyline for Prevention of Post-operative Pain in Women After Total Abdominal Hysterectomy: a Randomized Clinical Trial[NCT03587025] | Phase 3 | 150 participants (Actual) | Interventional | 2015-06-01 | Completed | ||
| Efficacy of Different Doses of Pregabalin as a Multimodal Analgesic Agent in Postoperative Pain Control After Total Knee Arthroplasty - A Randomized Controlled Trial[NCT05447364] | Phase 4 | 82 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | ||
| Comparison of Oral Lamotrigine Versus Pregabalin for Control of Acute and Chronic Pain Following Modified Radical Mastectomy: Controlled Double-blind Study[NCT03419949] | 0 participants | Expanded Access | Available | ||||
| Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM)[NCT04246619] | Phase 4 | 254 participants (Actual) | Interventional | 2019-11-12 | Terminated (stopped due to The statistical analysis will still provide relevant results with the same statistical power as initially planned.COVID-19 pandemic prolonged the recruiting period and consequently affected the costs of the clinical trial.) | ||
| Effects of Intra-Operative Ropivaciane Epidural Injection on Post-Operative Outcomes Following Elective Lumbar Fusion[NCT03035656] | Phase 4 | 228 participants (Anticipated) | Interventional | 2019-03-01 | Not yet recruiting | ||
| Double Blind Trial Investigating the Role of Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients[NCT03847311] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-05-03 | Recruiting | ||
| Confirmatory Study of Efficacy and Safety of the Pregabalin/Tramadol Combination Versus Pregabalin in the Management of Acute Pain of Neuropathic Origin.[NCT05324059] | Phase 3 | 110 participants (Actual) | Interventional | 2022-07-11 | Completed | ||
| Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain[NCT00637975] | Phase 2 | 80 participants (Anticipated) | Interventional | 2007-09-30 | Completed | ||
| Effect of Two Different Doses of Oral Pregabalin Premedication for Postoperative Pain Relief After Gynecological Surgeries[NCT04708353] | 90 participants (Anticipated) | Interventional | 2020-08-20 | Recruiting | |||
| Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
| Effects of Transverse Abdominis Plane Block Guided by Ultrasound on the Postoperative Analgesia and Quality of Lives Among the Patients Undergo Inguinal Hernia Repair[NCT02292095] | Phase 4 | 260 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| Comparison of the Analgesic Effect Between the Motor Cortex Stimulation (tDCS and rTMS) and the Trans-spinal Stimulation (tsDCS ) in the Algoneurodystrophy of Members. A Randomised Clinical Trial. tDCS : Transcranial Direct-current Stimulation rTMS : Repe[NCT02817880] | 36 participants (Actual) | Interventional | 2016-07-25 | Completed | |||
| Primary Motor Cortex Plasticity and the Bottom up Effect of Deep Intramuscular Needling Stimulation Therapy (DIMST)in Osteoarthritis Chronic Pain[NCT01855958] | 26 participants (Actual) | Interventional | 2012-02-29 | Completed | |||
| Effect of Transcranial Direct Current Stimulation and Electro Acupuncture in Pain, Functional Capability and Cortical Excitability in Patients With Osteoarthritis.[NCT01747070] | 60 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| The Efficacy Of Gabapentin In The Management Of Chemotherapy-Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind, Placebo-Controlled, Crossover Trial[NCT00027963] | Phase 3 | 100 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy[NCT03571334] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-07-08 | Recruiting | ||
| STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis[NCT05603702] | Phase 1 | 24 participants (Anticipated) | Interventional | 2023-03-17 | Recruiting | ||
| Persistent Postoperative Pain Incidence With Long Term Perioperative Gabapentin Used[NCT02693821] | Phase 4 | 122 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Single Blinded, Randomized Control Trial of High Frequency Stimulation in Subjects With Precision® Spinal Cord Stimulator System to Assess Efficacy and Preferability in Back and Extremity Pain Relief[NCT02265848] | Phase 4 | 22 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Identification of Differentially Expressed Genes in RNAseq Data of Patients With Failed Back Surgery Syndrome Treated With Different Modalities of Spinal Cord Stimulation: Looking for Biomarkers of Response and Effectiveness[NCT05712980] | 40 participants (Anticipated) | Observational | 2023-02-28 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A 21-item, patient-completed questionnaire to assess characteristics of depression. Each of the 21 items corresponding to a symptom of depression is summed to give a single score. There is a four-point scale for each item ranging from 0 to 3. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.57 |
| Duloxetine | -3.13 |
| Gabapentin + Duloxetine | -2.54 |
Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | kilogram (Least Squares Mean) |
|---|---|
| Pregabalin | 1.00 |
| Duloxetine | -2.39 |
| Gabapentin + Duloxetine | -1.06 |
Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Pregabalin | -1.30 |
| Duloxetine | 0.80 |
| Gabapentin + Duloxetine | 1.05 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the average pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Gabapentin + Duloxetine | -2.39 |
| Duloxetine | -2.62 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the average pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.12 |
| Duloxetine | -2.62 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the daily nighttime pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.30 |
| Duloxetine | -2.71 |
| Gabapentin + Duloxetine | -2.49 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the daily worst pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.59 |
| Duloxetine | -3.08 |
| Gabapentin + Duloxetine | -2.86 |
This is a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved at endpoint. It is based on a comparison between baseline and endpoint scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 65 |
| Duloxetine | 68 |
| Gabapentin + Duloxetine | 72 |
This is a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved at endpoint. It is based on a comparison between baseline and endpoint scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 59 |
| Duloxetine | 64 |
| Gabapentin + Duloxetine | 68 |
Elevated heart rate: >=100 beats per minute (bpm) + an increase of >=10 bpm if baseline <100 bpm. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 2 |
| Duloxetine | 9 |
| Gabapentin + Duloxetine | 6 |
This is a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved at endpoint. It is based on a comparison between baseline and endpoint scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 48 |
| Duloxetine | 50 |
| Gabapentin + Duloxetine | 47 |
A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). (NCT00385671)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin | 3.03 |
| Duloxetine | 3.01 |
| Gabapentin + Duloxetine | 2.83 |
Number of participants who discontinued. The reasons for discontinuation are presented in the participant flow. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 38 |
| Duloxetine | 51 |
| Gabapentin + Duloxetine | 36 |
This is the number of days required to first achieve a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved. It is based on a comparison between baseline and post-baseline scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | days (Median) |
|---|---|
| Pregabalin | 56.0 |
| Duloxetine | 35.0 |
| Gabapentin + Duloxetine | 28.0 |
This is the number of days required to first achieve a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved. It is based on a comparison between baseline and post-baseline scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | days (Median) |
|---|---|
| Pregabalin | 35.0 |
| Duloxetine | 28.0 |
| Gabapentin + Duloxetine | 28.0 |
The Portland Neurotoxicity Scale is a 15-item, patient-completed questionnaire designed to assess the degree of impact of anti-epileptic drug therapy on a number of cognitive and somatomotor parameters. Categories: better=negative change in score; same=no change in score; worse=positive change in score. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| better, total; n=122, n=126, n=128 | same, total; n=122, n=126, n=128 | worse, total; n=122, n=126, n=128 | better, cognitive toxicity; n=126, n=129, n=128 | same, cognitive toxicity; n=126, n=129, n=128 | worse, cognitive toxicity; n=126, n=129, n=128 | better, somatomotor toxicity; n=122, n=126, n=129 | same, somatomotor toxicity; n=122, n=126, n=129 | worse, somatomotor toxicity; n=122, n=126, n=129 | |
| Duloxetine | 84 | 5 | 37 | 80 | 6 | 43 | 74 | 19 | 33 |
| Gabapentin + Duloxetine | 86 | 4 | 38 | 82 | 5 | 41 | 74 | 19 | 36 |
| Pregabalin | 68 | 8 | 46 | 75 | 9 | 42 | 60 | 15 | 47 |
The Resource Utilization Scale measures direct and indirect costs (collected only for US sites). Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Inpatient costs include costs associated with hospitalizations and time spent in emergency rooms and psychiatric rooms. Outpatient costs include costs associated with visits to various health care providers, home health care by health care providers, and partial care. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| hours worked, greater, n=86, n=90, n=83 | hours worked, same, n=86, n=90, n=83 | hours worked, lower, n=86, n=90, n=83 | hours volunteered, greater, n=86, n=91, n=82 | hours volunteered, same, n=86, n=91, n=82 | hours volunteered, lower, n=86, n=91, n=82 | psychiatric visits, greater, n=92, n=93, n=90 | psychiatric visits, same, n=92, n=93, n=90 | psychiatric visits, lower, n=92, n=93, n=90 | outpatient group visits, greater, n=91, n=92, n=91 | outpatient group visits, same, n=91, n=92, n=91 | outpatient group visits, lower, n=91, n=92, n=91 | outpatient ind. visits, greater, n=91, n=88, n=90 | outpatient ind. visits, same, n=91, n=88, n=90 | outpatient ind. visits, lower, n=91, n=88, n=90 | days of partial care, greater, n=93, n=95, n=90 | days of partial care, same, n=93, n=95, n=90 | days of partial care, lower, n=93, n=95, n=90 | nights of partial care, greater, n=92, n=95, n=91 | nights of partial care, same, n=92, n=95, n=91 | nights of partial care, lower, n=92, n=95, n=91 | ER visits-psychiatric, greater, n=93, n=94, n=91 | ER visits-psychiatric, same, n=93, n=94, n=91 | ER visits-psychiatric, lower, n=93, n=94, n=91 | ER visits-nonpsychiatric, greater,n=91, n=95, n=88 | ER visits-nonpsychiatric, same,n=91, n=95, n=88 | ER visits-nonpsychiatric, lower,n=91, n=95, n=88 | phone mental health, greater,n=94, n=95, n=90 | phone mental health, same,n=94, n=95, n=90 | phone mental health, lower,n=94, n=95, n=90 | nonpsychiatric visits, greater, n=89, n=94, n=83 | nonpsychiatric visits, same, n=89, n=94, n=83 | nonpsychiatric visits, lower, n=89, n=94, n=83 | unpaid care, greater, n=84, n=87, n=86 | unpaid care, same, n=84, n=87, n=86 | unpaid care, lower, n=84, n=87, n=86 | missed work caregiver, greater, n=6, n=9, n=5 | missed work caregiver, same, n=6, n=9, n=5 | missed work caregiver, lower, n=6, n=9, n=5 | paid care, greater, n=60, n=58, n=58 | paid care, same, n=60, n=58, n=58 | paid care, less, n=60, n=58, n=58 | |
| Duloxetine | 12 | 66 | 12 | 8 | 77 | 6 | 0 | 91 | 2 | 0 | 92 | 0 | 1 | 84 | 3 | 1 | 94 | 0 | 1 | 94 | 0 | 0 | 94 | 0 | 4 | 85 | 6 | 1 | 93 | 1 | 20 | 46 | 28 | 0 | 87 | 0 | 0 | 8 | 1 | 0 | 58 | 0 |
| Gabapentin + Duloxetine | 13 | 59 | 11 | 10 | 66 | 6 | 2 | 84 | 4 | 1 | 89 | 1 | 4 | 81 | 5 | 2 | 87 | 1 | 2 | 89 | 0 | 0 | 91 | 0 | 4 | 78 | 6 | 2 | 87 | 1 | 18 | 45 | 20 | 0 | 85 | 1 | 0 | 5 | 0 | 0 | 58 | 0 |
| Pregabalin | 10 | 65 | 11 | 7 | 66 | 13 | 2 | 88 | 2 | 0 | 90 | 1 | 3 | 84 | 4 | 2 | 91 | 0 | 1 | 91 | 0 | 0 | 91 | 2 | 3 | 83 | 5 | 1 | 92 | 1 | 24 | 44 | 21 | 2 | 82 | 0 | 0 | 6 | 0 | 0 | 60 | 0 |
14-item subject-rated scale assessing changes in sexual activity and functioning; structured interview/questionnaire, designed to measure medication related changes in sexual functioning. 5 dimensions of sexual behavior: pleasure; desire/frequency; desire/interest; arousal; orgasm. Total score: obtained across all 5 dimensions, ranges from 14 to 70. Subscale scores: desire/frequency=2-10; desire/interest=3-15; pleasure=1-5; arousal=3-15; orgasm=3-15. Higher scores = better sexual functioning. Categories: better=positive change in score; same=no change in score; worse=negative change in score. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| male, total, better; n=62, n=67, n=66 | male, total, same; n=62, n=67, n=66 | male, total, worse; n=62, n=67, n=66 | female, total, better; n=39, n=42, n=43 | female, total, same; n=39, n=42, n=43 | female, total, worse; n=39, n=42, n=43 | male, pleasure, better; n=64, n=67, n=69 | male, pleasure, same; n=64, n=67, n=69 | male, pleasure, worse; n=64, n=67, n=69 | female, pleasure, better; n=40, n=42, n=43 | female, pleasure, same; n=40, n=42, n=43 | female, pleasure, worse; n=40, n=42, n=43 | male, desire/frequency, better; n=65, n=67, n=69 | male, desire/frequency, same; n=65, n=67, n=69 | male, desire/frequency, worse; n=65, n=67, n=69 | female, desire/frequency, better; n=42, n=42, n=43 | female, desire/frequency, same; n=42, n=42, n=43 | female, desire/frequency, worse; n=42, n=42, n=43 | male, desire/interest, better; n=65, n=67, n=70 | male, desire/interest, same; n=65, n=67, n=70 | male, desire/interest, worse; n=65, n=67, n=70 | female, desire/interest, better; n=42, n=42, n=45 | female, desire/interest, same; n=42, n=42, n=45 | female, desire/interest, worse; n=42, n=42, n=45 | male, arousal, better; n=65, n=67, n=70 | male, arousal, same; n=65, n=67, n=70 | male, arousal, worse; n=65, n=67, n=70 | female, arousal, better; n=40, n=42, n=45 | female, arousal, same; n=40, n=42, n=45 | female, arousal, worse; n=40, n=42, n=45 | male, orgasm, better; n=64, n=67, n=69 | male, orgasm, same; n=64, n=67, n=69 | male, orgasm, worse; n=64, n=67, n=69 | female, orgasm, better; n=40, n=42, n=43 | female, orgasm, same; n=40, n=42, n=43 | female, orgasm, worse; n=40, n=42, n=43 | |
| Duloxetine | 26 | 9 | 32 | 23 | 5 | 14 | 11 | 40 | 16 | 16 | 21 | 5 | 20 | 29 | 18 | 12 | 21 | 9 | 18 | 19 | 30 | 18 | 14 | 10 | 24 | 29 | 14 | 18 | 10 | 14 | 18 | 31 | 18 | 17 | 13 | 12 |
| Gabapentin + Duloxetine | 31 | 11 | 24 | 18 | 7 | 18 | 21 | 32 | 16 | 6 | 32 | 5 | 24 | 23 | 22 | 12 | 24 | 7 | 26 | 17 | 27 | 16 | 17 | 12 | 23 | 33 | 14 | 15 | 16 | 14 | 17 | 29 | 23 | 11 | 16 | 16 |
| Pregabalin | 24 | 9 | 29 | 13 | 5 | 21 | 13 | 39 | 12 | 10 | 23 | 7 | 12 | 36 | 17 | 11 | 21 | 10 | 20 | 19 | 26 | 13 | 12 | 17 | 20 | 28 | 17 | 11 | 14 | 15 | 12 | 29 | 23 | 15 | 13 | 12 |
Presented are numbers of participants who discontinued due to a change from baseline in laboratory analytes or vital signs. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Increased blood creatinine | Increased blood glucose | |
| Duloxetine | 0 | 0 |
| Gabapentin + Duloxetine | 1 | 0 |
| Pregabalin | 0 | 1 |
Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | millimeter mercury (Least Squares Mean) | |
|---|---|---|
| Diastolic | Systolic | |
| Duloxetine | 2.24 | -3.08 |
| Gabapentin + Duloxetine | -0.79 | -2.08 |
| Pregabalin | 0.18 | -3.31 |
A self-reported scale that measures the interference of pain in the past 24 hours on enjoyment of life. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.63 | -2.09 |
| Gabapentin + Duloxetine | 5.02 | -2.33 |
| Pregabalin | 4.38 | -1.82 |
A self-reported scale that measures the interference of pain in the past 24 hours on mood. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.08 | -1.85 |
| Gabapentin + Duloxetine | 4.10 | -1.43 |
| Pregabalin | 3.42 | -1.46 |
A self-reported scale that measures the interference of pain in the past 24 hours on normal work. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.98 | -1.86 |
| Gabapentin + Duloxetine | 5.15 | -1.88 |
| Pregabalin | 4.61 | -1.63 |
A self-reported scale that measures the interference of pain in the past 24 hours on relations with other people. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 3.08 | -1.27 |
| Gabapentin + Duloxetine | 3.29 | -1.17 |
| Pregabalin | 2.96 | -0.97 |
A self-reported scale that measures the interference of pain in the past 24 hours on sleep. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.97 | -2.12 |
| Gabapentin + Duloxetine | 5.40 | -2.50 |
| Pregabalin | 4.91 | -2.29 |
A self-reported scale that measures the interference of pain in the past 24 hours on walking ability. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.52 | -2.56 |
| Gabapentin + Duloxetine | 5.79 | -2.09 |
| Pregabalin | 5.25 | -1.88 |
A self-reported scale that measures the interference of pain in the past 24 hours on general activity. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.03 | -2.38 |
| Gabapentin + Duloxetine | 5.03 | -1.86 |
| Pregabalin | 4.24 | -1.51 |
The Interference scores range from 0 (does not interfere) to 10 (completely interferes). There are 7 questions assessing the interference of pain in the past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.61 | -2.00 |
| Gabapentin + Duloxetine | 4.83 | -1.90 |
| Pregabalin | 4.25 | -1.62 |
A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.65 | -2.44 |
| Gabapentin + Duloxetine | 5.75 | -2.29 |
| Pregabalin | 5.53 | -1.80 |
A self-reported scale that measures the severity of pain based on the least pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.18 | -1.55 |
| Gabapentin + Duloxetine | 4.07 | -1.54 |
| Pregabalin | 4.23 | -1.27 |
A self-reported scale that measures the severity of pain based on the pain right now. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.03 | -2.24 |
| Gabapentin + Duloxetine | 5.36 | -2.19 |
| Pregabalin | 4.98 | -1.77 |
A self-reported scale that measures the severity of pain based on the worst pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 Weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 6.87 | -3.02 |
| Gabapentin + Duloxetine | 7.00 | -2.64 |
| Pregabalin | 6.73 | -2.34 |
Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.47 | -1.16 |
| Gabapentin + Duloxetine | 4.40 | -1.13 |
| Pregabalin | 4.27 | -1.06 |
(NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | millimole/liter (Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 8.45 | 0.19 |
| Gabapentin + Duloxetine | 7.99 | 0.67 |
| Pregabalin | 8.24 | 0.16 |
(NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | percent (Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 7.51 | -0.01 |
| Gabapentin + Duloxetine | 7.16 | 0.07 |
| Pregabalin | 7.57 | -0.12 |
Aspartate aminotransferase = AST Alanine aminotransferase = ALT Gamma glutamyl transferase = GGT Alkaline phosphatase = AlkPhos (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units/liter (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| baseline, AST, n=119, n=121, n=118 | change, AST, n=119, n=121, n=118 | baseline, ALT, n=120, n=122, n=120 | change, ALT, n=120, n=122, n=120 | baseline, GGT, n=121, n=123, n=120 | change, GGT, n=121, n=123, n=120 | baseline, AlkPhos, n=121, n=123, n=120 | change, AlkPhos, n=121, n=123, n=120 | |
| Duloxetine | 22.84 | -0.52 | 25.04 | -0.16 | 34.29 | -3.03 | 83.74 | 0.55 |
| Gabapentin + Duloxetine | 23.42 | -0.48 | 24.39 | 0.03 | 43.93 | -2.55 | 82.18 | 1.78 |
| Pregabalin | 22.55 | 1.12 | 23.88 | -0.13 | 40.80 | 1.17 | 84.97 | 2.80 |
The LSEQ assesses the effects of psychoactive compounds on sleep and early morning behavior. Participants mark a series of 100 mm line analogue scales, indicating the direction and magnitude of any changes in behavioral state they experience following administration of the drug. Scores are represented in millimeters, higher scores indicate better sleep and better early morning behavior. Subscale score ranges: GTS=0-300, QOS=0-200, AFS=0-200, BFW=0-300. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| GTS, n=122, n=119, n=118 | QOS, n=121, n=118, n=118 | AFS, n=122, n=118, n=118 | BFW, n=124, n=115, n=118 | |
| Duloxetine | 17.40 | 7.39 | 8.14 | 21.04 |
| Gabapentin + Duloxetine | 14.75 | 9.64 | 11.86 | 14.33 |
| Pregabalin | 10.96 | 9.32 | 10.02 | 19.67 |
The Portland Neurotoxicity Scale is a 15-item, patient-completed questionnaire designed to assess the degree of impact of anti-epileptic drug therapy on a number of cognitive and somatomotor parameters. The total score ranges from 15-135 with higher scores indicating more toxicity. The cognitive toxicity score ranges from 10-90 and the somatomotor toxicity score ranges from 5-45, for both higher scores indicate more toxicity. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| total, n=122, n=126, n=128 | cognitive toxicity, n=126, n=129, n=128 | somatomotor toxicity, n=122, n=126, n=129 | |
| Duloxetine | -8.92 | -6.23 | -2.58 |
| Gabapentin + Duloxetine | -7.29 | -5.29 | -1.91 |
| Pregabalin | -6.27 | -5.12 | -1.36 |
14-item subject-rated scale assessing medication related changes in sexual activity + functioning. Structured interview/questionnaire. It measures five dimensions of sexual behavior: pleasure; desire/frequency; desire/interest; arousal; and orgasm. The total score is obtained across all 5 dimensions, ranging from 14 to 70. Subscale score ranges: desire/frequency=2-10; desire/interest=3-15; pleasure=1-5; arousal=3-15; orgasm=3-15. Higher scores = better sexual functioning. Least-squares means: adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| male, total; n=62, n=67, n=66 | female, total; n=39; n=42, n=43 | male, pleasure; n=64, n=67, n=69 | female, pleasure; n=40, n=42, n=43 | male, desire/frequency; n=65, n=67, n=69 | female, desire/frequency; n=42, n=42, n=43 | male, desire/interest; n=65, n=67, n=70 | female, desire/interest; n=42, n=42, n=45 | male, arousal; n=65, n=67, n=70 | female, arousal; n=40, n=42, n=45 | male, orgasm; n=64, n=67, n=69 | female, orgasm; n=40, n=42, n=43 | |
| Duloxetine | 0.48 | 1.12 | -0.06 | 0.47 | 0.06 | 0.26 | -0.19 | 0.34 | 0.52 | 0.07 | 0.18 | -0.05 |
| Gabapentin + Duloxetine | 1.29 | -0.61 | 0.13 | -0.09 | 0.16 | 0.30 | 0.05 | 0.01 | 0.52 | -0.30 | 0.17 | -0.85 |
| Pregabalin | -0.53 | -0.01 | 0.08 | 0.15 | -0.02 | 0.21 | -0.27 | -0.17 | 0.17 | -0.11 | -0.39 | 0.31 |
The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total scores range from 0 to 30, higher values indicate greater disruption in the patient's life. Item 1 assesses the effect of the patient's symptoms on their work/school schedule, Item 2 on their social life/leisure activities, and Item 3 on their family life/home responsibilities. Subscales scores range: 0-10, higher values indicate greater disruption in the patient's life. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Total | Item 1 | Item 2 | Item 3 | |
| Duloxetine | -3.47 | -1.21 | -1.12 | -1.17 |
| Gabapentin + Duloxetine | -4.54 | -1.95 | -1.53 | -1.54 |
| Pregabalin | -4.96 | -1.96 | -1.64 | -1.70 |
(NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | micromole/liter (Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 8.07 | -0.28 |
| Gabapentin + Duloxetine | 8.23 | -0.42 |
| Pregabalin | 8.43 | -0.51 |
"Treatment-emergent high body weight: weight at last visit >=107% of baseline weight.~Treatment-emergent low body weight: weight at last visit <=93% of baseline weight." (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| high | low | |
| Duloxetine | 1 | 10 |
| Gabapentin + Duloxetine | 3 | 8 |
| Pregabalin | 6 | 2 |
"Elevated systolic blood pressure: >=130 millimeter mercury (mm Hg) + an increase of >=10 mm Hg if baseline <130 mm Hg.~Elevated diastolic blood pressure: >=85 mm Hg + an increase of >=10 mm Hg if baseline <85 mm Hg." (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| diastolic, n=94, n=98, n=100 | systolic, n=42, n=39, n=56 | |
| Duloxetine | 12 | 15 |
| Gabapentin + Duloxetine | 13 | 16 |
| Pregabalin | 11 | 20 |
Treatment-emergent: within range at baseline, out of range after baseline. Ranges in Units/Liter (U/L). Aspartate Aminotransferase (AST): female (f): >34, male (m): >36. Alanine Aminotransferase (ALT): f:<69 years (yr) >34, ≥69yr >32; m: <69yr >43, ≥69yr >35. Total Bilirubin (TBili): >21. Gamma Glutamyl Transferase (GGT): f: <59yr >49, ≥59yr >50; m: <59yr >61, ≥59yr >50. Fasting Plasma Glucose (FPG): <59yr >6.4, ≥59yr >6.7. Hemoglobin A1C (HbA1C) >6%. Alkaline Phosphatase (AlkPhos): f: 18-50yr >106, 50-70yr >123, 70-80yr >164, ≥80yr >221; m: 18-50yr >129, 50-70yr >131, 70-80yr >156, ≥80yr >187 (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| AST, n=113, n=116, n=109 | ALT, n=111, n=104, n=110 | TBili, n=119, n=121, n=116 | GGT, n=102, n=105, n=96 | FPG, n=33, n=30, n=36 | HbA1C, n=17, n=18, n=29 | AlkPhos, n=112, n=114, n=113 | |
| Duloxetine | 6 | 6 | 0 | 6 | 11 | 2 | 3 |
| Gabapentin + Duloxetine | 4 | 10 | 0 | 6 | 18 | 10 | 4 |
| Pregabalin | 4 | 3 | 2 | 2 | 7 | 6 | 4 |
Contribution to reduction in pain directly by treatment and indirectly by treatment through the reduction of depressive symptoms using path analysis. The direct treatment effect estimates the mean drug difference in pain reduction directly through treatment; the indirect treatment effect estimates the contribution that treatment plays to the mean drug difference in pain reduction indirectly through the reduction in mood symptoms; the total effect estimates the drug difference in reducing pain in sum through the specified path of direct and indirect treatment effects. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | coefficient (Number) | ||
|---|---|---|---|
| Direct Treatment Effect | Indirect Treatment Effect | Total Treatment Effect | |
| Ordinary Coefficient | -0.449 | 0.014 | -0.435 |
(NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nausea | Peripheral Oedema | Insomnia | Somnolence | Anxiety | Dizziness | Dysuria | Headache | Hyperhidrosis | Sedation | Allergic Oedema | Anorgasmia | Increased Blood Creatine | Increased Blood Glucose | Bruxism | Cerebrovascular Accident | Chest Discomfort | Depression | Dermatitis | Diarrhoea | Dry mouth | Enterovirus Infection | Fatigue | Generalized Oedema | Facial Hypoaesthesia | Lacunar Infarction | Loss of Consciousness | Lymphoma | Mental Impairment | Muscular Weakness | Myoclonus | Pollakiuria | Pulomnary Embolism | Rash | Sleep Disorder | Urticaria | Vomiting | |
| Duloxetine | 4 | 0 | 4 | 2 | 1 | 0 | 2 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Gabapentin + Duloxetine | 4 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Pregabalin | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Ordinal scale: 0=no pain, 10=worst possible pain. Data=weekly mean of scores of average pain severity over last 24 hours (h). Scores: daily assessments recorded by patients in diaries. Only patients adhering to key protocol criteria included: baseline Weekly Mean 24h Average Pain Score ≥4; 80-120% compliant with study Drug, each visit; baseline Michigan Neuropathy Screening Instrument Physical Assessment Total Score ≥3; gabapentin taper ≤14 days, no HbA1c ≥12% post randomization; no contraindicated medications used. Least-squares means=adjustment due to baseline severity + investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 6.02 | -2.58 |
| Gabapentin + Duloxetine | 5.74 | -2.40 |
| Pregabalin | 5.74 | -2.12 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the average pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. De novo: use of gabapentin for <56 contiguous days prior to randomization. Prior use: use of gabapentin for >=56 contiguous days prior to randomization. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| de novo, baseline | de novo, week 1 | de novo, week 2 | de novo, week 3 | de novo, week 4 | de novo, week 5 | de novo, week 6 | de novo, week 7 | de novo, week 8 | de novo, week 9 | de novo, week 10 | de novo, week 11 | de novo, week 12 | prior use, baseline | prior use, week 1 | prior use, week 2 | prior use, week 3 | prior use, week 4 | prior use, week 5 | prior use, week 6 | prior use, week 7 | prior use, week 8 | prior use, week 9 | prior use, week 10 | prior use, week 11 | prior use, week 12 | |
| Duloxetine | 5.39 | -0.71 | -1.22 | -1.83 | -2.35 | -2.65 | -2.64 | -2.73 | -2.78 | -2.89 | -2.86 | -2.98 | -3.08 | 5.99 | -0.48 | -0.99 | -1.32 | -1.61 | -1.95 | -2.03 | -2.14 | -2.16 | -2.38 | -2.45 | -2.46 | -2.46 |
| Gabapentin + Duloxetine | 5.49 | -0.38 | -1.10 | -1.62 | -1.67 | -1.81 | -1.88 | -2.07 | -2.06 | -2.10 | -1.92 | -2.09 | -2.10 | 5.92 | -0.65 | -1.28 | -1.68 | -1.75 | -1.96 | -1.98 | -2.17 | -2.31 | -2.37 | -2.44 | -2.41 | -2.53 |
| Pregabalin | 5.24 | -0.22 | -0.39 | -0.71 | -0.84 | -0.95 | -1.09 | -1.08 | -1.26 | -1.21 | -1.42 | -1.48 | -1.62 | 5.91 | -0.30 | -0.70 | -1.18 | -1.64 | -1.72 | -1.92 | -1.93 | -1.89 | -2.04 | -2.14 | -2.27 | -2.39 |
Epidural medication consumption was recorded for each 4-h interval from the completion of surgery to the time that the epidural was discontinued (same as the time to achieve hospital discharge criteria). Because the discontinuation time varied from patient to patient (as they achieved physical therapy criteria), the average hourly consumption (total analgesic used divided by the total infusion time) was used as the measure of epidural drug use. (NCT00558753)
Timeframe: 36 h
| Intervention | mL/h (Mean) |
|---|---|
| 1 Placebo | 6.40 |
| 2 Pregabalin | 5.77 |
(NCT00558753)
Timeframe: 1-30 days
| Intervention | Degrees (Least Squares Mean) | |||
|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 30 | |
| 1 Placebo | 75.6 | 76.7 | 80.4 | 103.0 |
| 2 Pregabalin | 77.8 | 81.0 | 84.2 | 107.2 |
Patients will be evaluated in blinded fashion for lower extremity Complex Regional Pain Syndrome(CRPS) at pre-op, 1, 3, and 6 months postsurgery based initially on telephone interviews. An S-LANSS score of 12 or more was an indication of chronic neuropathic pain. Patients with an Self-report version of the Leeds Assessment of Neuropathic Symptoms and Signs(S-LANSS) score of 12 or more at 6 mo came to the physician's office for a standardized physical examination, which included the S-LANSS examination items (allodynia and hyperalgesia) directly assessed by the physician, plus a pinprick evaluation. (NCT00558753)
Timeframe: 3 and 6 months post-surgery
| Intervention | participants (Number) | |
|---|---|---|
| Neuropathic pain at 3 Month Follow up | Neuropathic pain at 6 Month Follow up | |
| 1 Placebo | 10 | 6 |
| 2 Pregabalin | 0 | 0 |
"PPT during cold water immersion (PPT+CPM): By measuring PPT during cold water immersion, we evaluated the degree to which pain perception is modulated by conditioned pain modulation (CPM) following the presentation of an initial heterotopic noxious stimulus. Subjects immersed their left hands into cold water (zero to 1°C) for 1 minute. During the last 30 seconds of cold-water immersion, the PPT procedure was administered at the right forearm. The temperature was held constant across during the experiment for each subject.~# Below the data after intervention." (NCT01855958)
Timeframe: Before and within one hour after intervention.
| Intervention | Kgf / cm2 (Mean) |
|---|---|
| DIMST | 12.62 |
| Placebo-sham | 9.15 |
"To determine the cortical silent period (CSP), subjects were instructed to squeeze the dynamometer using their fingers at 20% of maximal force when a single pulse stimulus (130% rMT) was applied. The result was the average of five consecutive measurements. The CSP was determined by the interval between the stimulus and the motor response elicited in the subject.~# Below the data after intervention." (NCT01855958)
Timeframe: Evaluated before and within one hour after intervention.
| Intervention | ms (milliseconds). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 50.93 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 48.92 |
"ICF was evaluated using an inter-stimuli intervals (ISIs) of 12 ms with paired-pulse and similar parameters for the conditioning and test stimuli. After a randomized protocol, thirty stimuli were assessed using a 2ms interval (ICI), a 12ms interval (ICF) and test-only trials (MEP). The resulting MEP amplitude was converted into the mean amplitude, and paired-pulse parameters were expressed as the amount of inhibition or facilitation. The calculation result of ICF was done by the ratio of the mean ICF by the mean MEP.~# Below the data after intervention." (NCT01855958)
Timeframe: Before and within one hour after intervention.
| Intervention | ratio of amplitude (mV). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 1.20 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 0.78 |
"ICI was evaluated using inter-stimuli intervals (ISIs) of 2 ms with paired-pulse stimulation. The subthreshold stimulus was set at 80% of rMT (conditioning stimulus) , and the suprathreshold test stimulus was set at 130% of rMT. After a randomized protocol, thirty stimuli were assessed using a 2ms interval (ICI), a 12ms interval (ICF) and test-only trials (MEPs). The resulting MEP amplitude was converted into the mean amplitude, and paired-pulse parameters were expressed as the amount of inhibition or facilitation. The calculation result of ICI was done by the ratio of the mean ICI by the mean MEP.~# Below the data after intervention." (NCT01855958)
Timeframe: Evaluated in one day. The cortical excitability before and within an hour after intervention.
| Intervention | ratio of amplitude (mV). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 0.75 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 0.57 |
"Cortical excitability was assessed using a MagPro X100 (MagVenture Company, Lucernemarken, Denmark) and a figure-of-8 coil centered over the left motor cortex (M1). Subjects were seated in a comfortable reclining chair with their arms and hands lying relaxed on the armrests. The investigators measured the resting motor threshold (rMT) of the right first dorsal interosseous (FDI) muscle. The MEPs were recorded by surface electromyography (EMG) using Ag-AgCl cup electrodes in a belly tendon montage. Resting motor threshold (rMT) was defined as the stimulus intensity at which peak-to-peak MEP amplitude of 50 µV (microvolts) was obtained in at least 5 of 10 consecutive trials.~MEP was defined as approximately 130% of the rMT or the stimulus intensity at which peak-to-peak MEP amplitude of at least 1 mV was obtained in 10 consecutive trials. The result of the MEP was the average of 10 curves (unconditioned MEP).~# Below the data after intervention." (NCT01855958)
Timeframe: Before and within one hour after intervention.
| Intervention | mV (millivolts). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 1.14 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 1.12 |
"The intensity of pain was measured by a 10-cm VAS. VAS scores ranged from no pain (zero) to the worst possible pain possible (10 cm). The pain score on VAS during the last 24 hours was used to classify the subjects into two groups: (1) absence of pain or mild pain (scores equal to or lower than 4 cm) and (2) moderate, intense, or worst possible pain (scores higher than 4 cm).~# Below the data after intervention." (NCT01855958)
Timeframe: Evaluated within twenty four hours before and within one hour after the intervention.
| Intervention | cm ( mean). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 0.88 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 3.36 |
"PPT (alone): The patient was instructed to verbally report the perception of pain onset. The investigator assessed PPT using an electronic algometer (J Tech Medical Industries, USA). The device had a 1-cm2 hard-rubber probe, which was applied over structures at L1- L5 dermatome at the knee and at the contralateral forearm. The average values of PPT in kgf/cm2 for three successive readings taken at intervals of 3-5 min were used as the outcomes.~# Below, the data after intervention." (NCT01855958)
Timeframe: Before and within one hour after intervention.
| Intervention | Kgf / cm2 (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 8.82 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 6.66 |
Digital pain rating system that scores patient's subjective pain rating from 0 to 10; with greater number indicating progressively worsening pain. NPRS were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Average Baseline NPRS Score | Average NPRS after 1000 Hz. stimulation | Average NPRS after standard stimulation | Average NPRS after Wash off | Best Baseline NPRS score | Best NPRS score after 1000 Hz. stimulation | Best NPRS score after standard stimulation | Best NPRS after Wash off | Worst Baseline NPRS score | Worst NPRS score after 1000 Hz. stimulation | Worst NPRS score after standard stimulation | Worst NPRS after Wash off | |
| Treatment Group A | 6.09 | 3.73 | 5.64 | 6.45 | 3.72 | 2.64 | 3.46 | 4.54 | 7.90 | 6.64 | 8.18 | 8.72 |
| Treatment Group B | 6.27 | 3.82 | 6.09 | 7.18 | 4.45 | 2.18 | 4.45 | 5.36 | 8.09 | 6.64 | 8.36 | 8.81 |
ODI is a outcome metrics that is design to assess the severity of disability based on 10 activity categories. ODI is based on 0 to 100% scale, where larger percentage implies worse disability. (There are 5 categories: 0-20%: Minimal disability, 21-40%: Moderate disability, 41-60%: Severe disability, 61-80%: Crippled. 81-100%: Either bed bound or exaggerating symptoms). ODI were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline ODI score | ODI after 1000 Hz. stimluation | ODI after standard stimulation | ODI after wash off | |
| Treatment Group A | 47.49 | 39.23 | 49.63 | 52.87 |
| Treatment Group B | 51.25 | 33.77 | 49.05 | 56.77 |
PGIC is a 7-point scale that requires study subjects to rate the severity of their illness or medical condition after a specific treatment. 1: No change, 2: Almost the same, 3: A little better, 4: Somewhat better, 5: Moderately better, 6: Better, 7: A great deal better. Study subjects were asked to report their impression of changes at baseline visit, visit 2 through 4. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| PGIC After 1000 Hz. stimulation | PGIC after standard stimulation | PGIC after Wash off | |
| Treatment Group A | 4.27 | 2.54 | 1.45 |
| Treatment Group B | 5.91 | 2.45 | 1.27 |
At the conclusion of the study, subjects were asked to report which spinal cord stimulation modes they preferred. Subjects were presented with two boxes (1000 Hz. stimulation and Standard stimulation) and asked to check one. (NCT02265848)
Timeframe: End of treatment visit on visit 4
| Intervention | participants (Number) | |
|---|---|---|
| Subjects who prefer 1000 Hz. stimulation | Subjects who prefer standard stimulation | |
| Treatment Group A | 8 | 3 |
| Treatment Group B | 10 | 1 |
30 reviews available for gamma-aminobutyric acid and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Mechanisms and management of diabetic painful distal symmetrical polyneuropathy.
Topics: Diabetic Neuropathies; Duloxetine Hydrochloride; gamma-Aminobutyric Acid; Humans; Pain; Peripheral N | 2013 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics.
Topics: Amines; Analgesics, Opioid; Animals; Antidepressive Agents; Antineoplastic Agents; Cisplatin; Cycloh | 2016 |
Itch Management: Systemic Agents.
Topics: Amines; Analgesics; Analgesics, Opioid; Anion Exchange Resins; Antidepressive Agents; Aprepitant; Ch | 2016 |
Neurologic Itch Management.
Topics: Acupuncture Therapy; Amines; Anesthetics, Local; Anticonvulsants; Antipruritics; Botulinum Toxins, T | 2016 |
Pregabalin in the treatment of chronic pain: an overview.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic | 2009 |
[Pain relief by gabapentin via supraspinal mechanisms in neuropathic conditions].
Topics: Amines; Analgesics; Animals; Brain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid | 2009 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
Gabapentin for the treatment of cancer-related pain syndromes.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2010 |
The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.
Topics: Academies and Institutes; Benzothiazoles; Cabergoline; Carbamates; Dopamine Agents; Ergolines; Evide | 2012 |
[Burning sensation in oral cavity--burning mouth syndrome in everyday medical practice].
Topics: Acetamides; Amines; Anti-Anxiety Agents; Antidepressive Agents; Antioxidants; Burning Mouth Syndrome | 2012 |
Mode of action of gabapentin in chronic neuropathic pain syndromes. A short review about its cellular mechanisms in nociceptive neurotransmission.
Topics: Acetates; Amines; Animals; Biogenic Monoamines; Calcium Channels; Chronic Disease; Cyclohexanecarbox | 2002 |
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anticonvu | 2003 |
Gabapentin in the treatment of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 2004 |
'Protective premedication': an option with gabapentin and related drugs? A review of gabapentin and pregabalin in in the treatment of post-operative pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Human | 2004 |
[Evidence-based pharmacotherapy of neuropathic pain syndromes].
Topics: Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Antioxidants; Cyclohexanec | 2004 |
Combination pharmacotherapy for neuropathic pain: current evidence and future directions.
Topics: Amines; Analgesics; Animals; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Synergism; | 2005 |
Pregabalin: a new neuromodulator with broad therapeutic indications.
Topics: Agoraphobia; Anxiety; Diabetic Neuropathies; Epilepsy; gamma-Aminobutyric Acid; Herpesviridae Infect | 2005 |
The mechanism of action of gabapentin in neuropathic pain.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Binding Sites; Calcium Channels; Cyclohexanecarboxylic Ac | 2006 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin for the treatment of painful neuropathy.
Topics: Analgesics; Clinical Trials as Topic; gamma-Aminobutyric Acid; Humans; Neuralgia; Peripheral Nervous | 2006 |
Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain.
Topics: Amines; Analgesics; Animals; Anticonvulsants; Calcium Channels; Carboxylic Acids; Cyclohexanecarboxy | 2007 |
Update on pharmacotherapy guidelines for treatment of neuropathic pain.
Topics: Analgesics; Animals; Cannabidiol; Chronic Disease; Dronabinol; Duloxetine Hydrochloride; gamma-Amino | 2007 |
Antiepileptic drugs in the treatment of neuropathic pain.
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Fructose; Gabapentin; gamma-Ami | 2007 |
Treatment of painful neuropathy.
Topics: Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gaba | 2007 |
Managing neuropathic pain.
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Calcium Channel Blockers; Combined Modality Therapy; Cy | 2007 |
[Pregabalin--a neuromodulator for the treatment of neuropathic pain, generalized anxiety disorders and fibromyalgia syndrome].
Topics: Analgesics; Anxiety Disorders; Fibromyalgia; gamma-Aminobutyric Acid; Humans; Pain; Peripheral Nervo | 2007 |
Lead neuropathy.
Topics: Aminolevulinic Acid; Animals; Electromyography; Electrophysiology; gamma-Aminobutyric Acid; Humans; | 1984 |
Gabapentin use in neuropathic pain syndromes.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 2000 |
Emerging cell and molecular strategies for the study and treatment of painful peripheral neuropathies.
Topics: Animals; Cell Line, Transformed; Cell Transplantation; Chromaffin Cells; gamma-Aminobutyric Acid; Ge | 2000 |
22 trials available for gamma-aminobutyric acid and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients.
Topics: Adult; Aged; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Female; Follow-Up | 2013 |
Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combi | 2014 |
Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial.
Topics: Acute Pain; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2016 |
Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies.
Topics: Adolescent; Adult; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Diphenhydram | 2009 |
Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; | 2009 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine.
Topics: Aged; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; | 2010 |
Pregabalin as mono- or add-on therapy for patients with refractory chronic neuropathic pain: a post-marketing prescription-event monitoring study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Chronic Disease; Cohort Studies; Drug Prescriptions; Dru | 2010 |
Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
Topics: Analgesics; Dose-Response Relationship, Drug; Double-Blind Method; Female; gamma-Aminobutyric Acid; | 2010 |
Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial.
Topics: Amines; Anti-Anxiety Agents; Calcium Channel Blockers; Cross-Over Studies; Cyclohexanecarboxylic Aci | 2013 |
Predicting response to pregabalin from pretreatment pain quality: clinical applications of the pain quality assessment scale.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Analgesics; Ethnicity; Female; gamma-Aminobutyric Acid; | 2013 |
Clinical efficacy of gabapentin for paroxysmal symptoms in multiple sclerosis.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami | 2004 |
A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2004 |
Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study.
Topics: Aged; Amines; Analgesics; Analysis of Variance; Cyclohexanecarboxylic Acids; Dose-Response Relations | 2005 |
Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions.
Topics: Adult; Age Distribution; Aged; Amines; Analgesics; Cohort Studies; Cross-Sectional Studies; Cyclohex | 2007 |
Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain.
Topics: Adult; Aged; Amines; Analgesics; Anxiety; Cyclohexanecarboxylic Acids; Depression; Disability Evalua | 2007 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Gabapentin adjunctive therapy in neuropathic pain states.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Facial Pain; Female; Gabapen | 1996 |
The effect of gabapentin on neuropathic pain.
Topics: Acetates; Adolescent; Adult; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Gabapentin; gam | 1997 |
Gabapentin for treatment of pain and tremor: a large case series.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Arachnoiditis; Cerebellar Neoplasms; Cyc | 1998 |
Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Central Nervous System Diseases; Cyclohexanecarboxyli | 1998 |
114 other studies available for gamma-aminobutyric acid and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Interleukin-17 Regulates Neuron-Glial Communications, Synaptic Transmission, and Neuropathic Pain after Chemotherapy.
Topics: Animals; Astrocytes; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; Humans; Interleuki | 2019 |
Efficiencies of Low-Level Laser Therapy (LLLT) and Gabapentin in the Management of Peripheral Neuropathy: Diabetic Neuropathy.
Topics: Amines; Animals; Combined Modality Therapy; Creatinine; Cyclohexanecarboxylic Acids; Cytokines; Diab | 2018 |
Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy.
Topics: Adult; Amines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclohexanecarboxylic Ac | 2018 |
Statistical identification of predictors for paclitaxel-induced peripheral neuropathy in patients with breast or gynaecological cancer.
Topics: Aged; Analgesics, Opioid; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; gamma-Aminobu | 2013 |
[Promising effects of pregabalin in the treatment of oxaliplatin-induced sensory neuropathy in patients with colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; gamma-Aminobutyric Acid; Humans; M | 2013 |
[Efficacy and safety of pregabalin for oxaliplatin- and paclitaxel-induced peripheral neuropathy].
Topics: Antineoplastic Agents; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Neoplasms; Organoplatinum | 2013 |
Comparison of the effects of single doses of elcatonin and pregabalin on oxaliplatin-induced cold and mechanical allodynia in rats.
Topics: Analgesics; Animals; Antineoplastic Agents; Calcitonin; Cold Temperature; gamma-Aminobutyric Acid; H | 2014 |
[On the Differential Diagnosis of Intractable Psychogenic Chronic Cough: Neuropathic Larynx Irritable - Gabapentin's Antitussive Action].
Topics: Aged; Amines; Avitaminosis; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Depressive Disorder | 2015 |
Therapeutic Implications of Peripheral Nerve Hyperexcitability in Muscle Cramping: A Retrospective Review.
Topics: Amines; Analgesics, Non-Narcotic; Antibodies; Carbamazepine; Cyclohexanecarboxylic Acids; Electric S | 2016 |
Multilevel symmetric neuropathic pruritus (MSNP) presenting as recalcitrant "generalized" pruritus.
Topics: Age Distribution; Aged; Amines; Chronic Disease; Cohort Studies; Cyclohexanecarboxylic Acids; Diseas | 2016 |
Peripheral nerve injury alters spinal nicotinic acetylcholine receptor pharmacology.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; gamma-Aminobutyric Acid; Male; Nicotine; Pain; Per | 2008 |
Tactile allodynia can occur in the spared nerve injury model in the rat without selective loss of GABA or GABA(A) receptors from synapses in laminae I-II of the ipsilateral spinal dorsal horn.
Topics: Animals; Denervation; Disease Models, Animal; Functional Laterality; gamma-Aminobutyric Acid; Hypera | 2008 |
Multiplicative interactions to enhance gabapentin to treat neuropathic pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Donepezil; Dose-Response Relationship, Dru | 2008 |
Neuropathic pain in children after exposure to mercury.
Topics: Amines; Analgesics, Non-Narcotic; Burning Mouth Syndrome; Child; Cyclohexanecarboxylic Acids; Gabape | 2008 |
A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling.
Topics: Adult; Aged; Algorithms; Amines; Area Under Curve; Bayes Theorem; Biological Availability; Cyclohexa | 2009 |
Peripheral neuropathy in an adolescent treated with linezolid.
Topics: Acetamides; Amines; Analgesics; Anti-Bacterial Agents; Child; Cyclohexanecarboxylic Acids; Female; G | 2009 |
Topical analgesic combinations for bortezomib neuropathy.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Amines; Analgesics; Boronic Acids; Bortezomib; C | 2009 |
Oral pregabalin reverses cold allodynia in two distinct models of peripheral neuropathic pain.
Topics: Administration, Oral; Analgesics; Animals; Behavior, Animal; Chronic Disease; Cold Temperature; Dise | 2009 |
Alopecia associated with gabapentin in the treatment of neuropathic pain.
Topics: Alopecia; Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A | 2009 |
Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit.
Topics: Administration, Oral; Amines; Analgesics, Non-Narcotic; Animals; Antineoplastic Agents; Antineoplast | 2009 |
A mouse model of sural nerve injury-induced neuropathy: gabapentin inhibits pain-related behaviors and the hyperactivity of wide-dynamic range neurons in the dorsal horn.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Behavior, Animal; Cold Temperature; Cyclohexanecarboxylic | 2009 |
Blood serum profiling of the rat spinal nerve ligation model using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry.
Topics: Amines; Analgesics; Animals; Biomarkers; Chromatography, High Pressure Liquid; Cyclohexanecarboxylic | 2009 |
Neuropathic pevic pain--a personal experience.
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Male; Pain, Postoperative; Pelvic Pain; Peripheral Nerv | 2008 |
[Obturator nerve lesion after a vaginal delivery without instrumentation under epidural analgesia].
Topics: Adult; Amines; Analgesia, Epidural; Analgesia, Obstetrical; Analgesics; Cyclohexanecarboxylic Acids; | 2009 |
How does gabapentin relieve neuropathic pain?
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Pain; | 2009 |
A new treatment option for laryngeal sensory neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Female; gamma-Aminobutyric Acid; Humans; Laryngeal | 2009 |
Electroconvulsive stimulation (ECS) increases the expression of neuropeptide Y (NPY) in rat brains in a model of neuropathic pain: a quantitative real-time polymerase chain reaction (RT-PCR) study.
Topics: Animals; Brain; Brain Chemistry; Disease Models, Animal; Electroconvulsive Therapy; gamma-Aminobutyr | 2009 |
Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy.
Topics: Aged; Amines; Analgesics; Cohort Studies; Cyclohexanecarboxylic Acids; Data Interpretation, Statisti | 2010 |
Spinal GABA receptors mediate the suppressive effect of electroacupuncture on cold allodynia in rats.
Topics: Animals; Cold Temperature; Denervation; Disease Models, Animal; Electroacupuncture; GABA Antagonists | 2010 |
A new combination cream for the treatment of severe neuropathic pain.
Topics: Administration, Topical; Analgesics; Capsaicin; Diabetic Neuropathies; Drug Combinations; gamma-Amin | 2010 |
Pain, in the boondocks.
Topics: Administration, Topical; Analgesics, Non-Narcotic; Animals; Behavior, Animal; gamma-Aminobutyric Aci | 2010 |
Attenuation of neuropathy-induced allodynia following intraplantar injection of pregabalin.
Topics: Analgesics, Non-Narcotic; Animals; Behavior, Animal; Cold Temperature; Dose-Response Relationship, D | 2010 |
Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
Topics: Amines; Analgesics, Opioid; Animals; Carrageenan; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Ex | 2010 |
New uses for older drugs: the tales of aspirin, thalidomide, and gabapentin.
Topics: Amines; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Aspirin; Cyclohexanecarboxylic Aci | 2010 |
Upregulation of the GABA transporter GAT-1 in the gracile nucleus in the spared nerve injury model of neuropathic pain.
Topics: Amino Acid Transport System X-AG; Animals; Astrocytes; Biological Transport; Excitatory Amino Acid T | 2010 |
Non-length-dependent small fibre neuropathy. Confocal microscopy study of the corneal innervation.
Topics: Adult; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Second-Generation; Antidepressive A | 2010 |
A tropomyosine receptor kinase inhibitor blocks spinal neuroplasticity essential for the anti-hypersensitivity effects of gabapentin and clonidine in rats with peripheral nerve injury.
Topics: Acetylcholine; Amines; Analgesics; Animals; Carbazoles; Choline O-Acetyltransferase; Clonidine; Cycl | 2011 |
Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
Topics: Aged; Amines; Analgesics; Case-Control Studies; Clinical Trials as Topic; Cyclohexanecarboxylic Acid | 2010 |
Gabapentin withdrawal syndrome in a post-liver transplant patient.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; | 2010 |
Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies.
Topics: Amines; Analgesics; Animals; Cholinesterase Inhibitors; Cyclohexanecarboxylic Acids; Disease Models, | 2010 |
Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study.
Topics: Aged; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Pain; Peripheral Nervo | 2011 |
Neuritis ossificans of the tibial, common peroneal and lateral sural cutaneous nerves.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans | 2011 |
Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain.
Topics: Aged; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; | 2012 |
Decreased intracellular GABA levels contribute to spinal cord stimulation-induced analgesia in rats suffering from painful peripheral neuropathy: the role of KCC2 and GABA(A) receptor-mediated inhibition.
Topics: Analgesia; Animals; Chronic Pain; Disease Models, Animal; Electric Stimulation Therapy; gamma-Aminob | 2012 |
Antinociceptive effect of Butea monosperma on vincristine-induced neuropathic pain model in rats.
Topics: Analgesics; Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Behavior, Animal; Butea; Calci | 2013 |
Peripheral neuropathy response to erythropoietin in type 2 diabetic patients with mild to moderate renal failure.
Topics: Aged; Aged, 80 and over; Amines; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Diabetic Ne | 2012 |
Peripheral nerve toxic effects of nitrofurantoin.
Topics: Amines; Analgesics; Anti-Infective Agents, Urinary; Biopsy; Cyclohexanecarboxylic Acids; Cystitis, I | 2012 |
Pemetrexed-induced cellulitis: a rare toxicity in non-small cell lung cancer treatment.
Topics: Adrenal Cortex Hormones; Aged; Amines; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Ca | 2013 |
Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Drug Int | 2012 |
[A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2012 |
Opioids before and after initiation of pregabalin in patients with diabetic peripheral neuropathy.
Topics: Adult; Analgesics, Opioid; Diabetes Complications; gamma-Aminobutyric Acid; Humans; Peripheral Nervo | 2012 |
[A case of paclitaxel-induced peripheral neuropathy successfully treated with pregabalin].
Topics: Antineoplastic Combined Chemotherapy Protocols; gamma-Aminobutyric Acid; Humans; Kidney Neoplasms; M | 2012 |
Ameliorative effect of Vernonia cinerea in vincristine-induced painful neuropathy in rats.
Topics: Animals; Behavior, Animal; Calcium; Female; gamma-Aminobutyric Acid; Glutathione; Hyperalgesia; Lipi | 2014 |
Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model.
Topics: Amines; Animals; Antioxidants; Calcium Channels; Catalase; Cyclohexanecarboxylic Acids; Drug Combina | 2013 |
Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord.
Topics: Animals; Blotting, Western; Cell Death; Disease Models, Animal; Excitatory Postsynaptic Potentials; | 2002 |
Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain.
Topics: Acetates; Amines; Animals; Benzofurans; Carbamates; Cyclohexanecarboxylic Acids; Diabetes Mellitus, | 2002 |
Anti-allodynic action of the tormentic acid, a triterpene isolated from plant, against neuropathic and inflammatory persistent pain in mice.
Topics: Acetates; Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Freund' | 2002 |
ATP-sensitive potassium channels in rat primary afferent neurons: the effect of neuropathic injury and gabapentin.
Topics: Acetates; Amines; Animals; ATP-Binding Cassette Transporters; Basal Ganglia; Cyclohexanecarboxylic A | 2003 |
Selective loss of spinal GABAergic or glycinergic neurons is not necessary for development of thermal hyperalgesia in the chronic constriction injury model of neuropathic pain.
Topics: Animals; Chronic Disease; gamma-Aminobutyric Acid; Glycine; Hot Temperature; Hyperalgesia; Male; Pai | 2003 |
Potent analgesic effects of anticonvulsants on peripheral thermal nociception in rats.
Topics: Acetates; Amines; Analgesics; Animals; Anticonvulsants; Calcium Channel Blockers; Carbamazepine; Cyc | 2003 |
[EFFECT OF GABOB AND A RELATED SUBSTANCE ON SPINAL CORD INJURIES AND PERIPHERAL PARALYSIS].
Topics: Amino Acids; Blood Circulation; Blood Pressure Determination; Cats; Electromyography; gamma-Aminobut | 1964 |
Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain.
Topics: Acetates; Amines; Analgesics; Animals; Anti-Inflammatory Agents; Cyclohexanecarboxylic Acids; Edema; | 2003 |
Removal of GABAergic inhibition facilitates polysynaptic A fiber-mediated excitatory transmission to the superficial spinal dorsal horn.
Topics: Animals; Denervation; Disease Models, Animal; Excitatory Amino Acid Antagonists; Excitatory Postsyna | 2003 |
Synergistic interaction between spinal gabapentin and oral B vitamins in a neuropathic pain model.
Topics: Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug | 2003 |
The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.
Topics: Acute Disease; Amines; Analgesics, Opioid; Animals; Carbamates; Cyclohexanecarboxylic Acids; Disease | 2004 |
American Chemical Society--227th annual meeting. Neuroprotection. 28 March - 1 April 2004, Anaheim, CA, USA.
Topics: Animals; Antiparkinson Agents; Carbazoles; gamma-Aminobutyric Acid; Humans; Indoles; Neuroprotective | 2004 |
Modulation of the gait deficit in arthritic rats by infusions of muscimol and bicuculline.
Topics: Animals; Arthralgia; Arthritis, Experimental; Body Weight; Disease Models, Animal; Dose-Response Rel | 2004 |
Future Pain Drugs - Europe 2003. 15-16 September 2003, London, UK.
Topics: Acetaminophen; Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, A | 2003 |
Differential analgesic sensitivity of two distinct neuropathic pain models.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Animals; Cold Temperature; Cyclohexanecarboxylic A | 2004 |
Gabapentin relieves mechanical, warm and cold allodynia in a rat model of peripheral neuropathy.
Topics: Amines; Animals; Cold Temperature; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Respons | 2004 |
Neutropenia occurring after starting gabapentin for neuropathic pain.
Topics: Adenocarcinoma; Amines; Analgesics; Carcinoma, Non-Small-Cell Lung; Cyclohexanecarboxylic Acids; Gab | 2004 |
Oral administration of B vitamins increases the antiallodynic effect of gabapentin in the rat.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Syn | 2004 |
[Peripheral neuropathic pain and epilepsy].
Topics: Analgesics; Anticonvulsants; Clinical Trials as Topic; Epilepsies, Partial; gamma-Aminobutyric Acid; | 2004 |
[Reducing pain by new forms of therapy].
Topics: Analgesics; Anticonvulsants; Calcium Channels; Drug Therapy, Combination; gamma-Aminobutyric Acid; H | 2004 |
Neuropathic pain following multilevel surgery in children with cerebral palsy: a case series and review.
Topics: Adolescent; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Cerebral Palsy; Chi | 2005 |
Effects of gabapentin on spontaneous discharges and subthreshold membrane potential oscillation of type A neurons in injured DRG.
Topics: Amines; Analgesics; Animals; Animals, Newborn; Cyclohexanecarboxylic Acids; Differential Threshold; | 2005 |
The effect of antinociceptive drugs tested at different times after nerve injury in rats.
Topics: Amines; Analgesics; Animals; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Dose-Res | 2005 |
Effect of morphine on deep dorsal horn projection neurons depends on spinal GABAergic and glycinergic tone: implications for reduced opioid effect in neuropathic pain.
Topics: Administration, Topical; Analgesics, Opioid; Animals; Behavior, Animal; Electrophysiology; gamma-Ami | 2005 |
Characterization of pain and pharmacologic responses in an animal model of lumbar adhesive arachnoiditis.
Topics: Amines; Analgesics; Analgesics, Opioid; Animals; Arachnoiditis; Behavior, Animal; Cauda Equina; Cycl | 2005 |
Neuropathies in the rheumatoid patient: a case of the heavy hand.
Topics: Amines; Arthritis, Rheumatoid; Cyclohexanecarboxylic Acids; Electromyography; Female; Follow-Up Stud | 2005 |
Development and expression of neuropathic pain in CB1 knockout mice.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2006 |
Differential pharmacological modulation of the spontaneous stimulus-independent activity in the rat spinal cord following peripheral nerve injury.
Topics: Action Potentials; Amines; Analgesics; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarbox | 2006 |
Spinal nerve ligation does not alter the expression or function of GABA(B) receptors in spinal cord and dorsal root ganglia of the rat.
Topics: Animals; Baclofen; Denervation; Disease Models, Animal; GABA Agonists; gamma-Aminobutyric Acid; Gang | 2006 |
Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin.
Topics: Amines; Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Blotting, Western; Calcium Cha | 2006 |
A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain.
Topics: Amines; Analgesics; Animals; Anticonvulsants; Cold Temperature; Cyclohexanecarboxylic Acids; Disease | 2007 |
Laryngeal neuropathy as a cause of chronic intractable cough.
Topics: Amines; Cough; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Ami | 2007 |
Nociception: Taking the Pain out of Drug Discovery. 28 November 2006, London, UK.
Topics: Amidohydrolases; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2007 |
[3H] pregabalin binding is increased in ipsilateral dorsal horn following chronic constriction injury.
Topics: Afferent Pathways; Analgesics; Animals; Binding, Competitive; Calcium Channel Blockers; Calcium Chan | 2007 |
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
Topics: Analgesics; Animals; Anticonvulsants; Disease Models, Animal; gamma-Aminobutyric Acid; Hyperalgesia; | 2007 |
Pregabalin does not impact peripheral nerve regeneration after crush injury.
Topics: Analgesics; Animals; Crush Syndrome; gamma-Aminobutyric Acid; Male; Nerve Regeneration; Peripheral N | 2007 |
Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine.
Topics: Adult; Aged; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Pain Measuremen | 2007 |
Gabapentin treatment for notalgia paresthetica, a common isolated peripheral sensory neuropathy.
Topics: Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric A | 2007 |
Gabapentin produces PKA-dependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice.
Topics: Amines; Animals; Cyclic AMP-Dependent Protein Kinases; Cyclohexanecarboxylic Acids; Efferent Pathway | 2008 |
Pharmacologic investigation of the mechanism underlying cold allodynia using a new cold plate procedure in rats with chronic constriction injuries.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Calcium Channel Blockers; Chronic Disease; Cold Tempe | 2008 |
Gabapentin and sexual dysfunction: report of two cases.
Topics: Adolescent; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2008 |
Rats with chronic post-ischemia pain exhibit an analgesic sensitivity profile similar to human patients with complex regional pain syndrome--type I.
Topics: Amitriptyline; Analgesics; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dos | 2008 |
Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffing in mice.
Topics: Amines; Amitriptyline; Animals; Anticonvulsants; Antidepressive Agents, Tricyclic; Brain; Chronic Di | 2008 |
Pharmacological treatment of neuropathic pain in older persons.
Topics: Aged; Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Chronic Disease | 2008 |
Autoantibodies to glutamate decarboxylase in a patient with cerebellar cortical atrophy, peripheral neuropathy, and slow eye movements.
Topics: Adult; Atrophy; Autoantibodies; Autoimmunity; Cerebellum; Eye Movements; Female; gamma-Aminobutyric | 1995 |
Roles of monoaminergic, glycinergic and GABAergic inhibitory systems in the spinal cord in rats with peripheral mononeuropathy.
Topics: Analysis of Variance; Animals; Biogenic Monoamines; Dizocilpine Maleate; Excitatory Amino Acid Antag | 1996 |
Effects of spinal cord stimulation on touch-evoked allodynia involve GABAergic mechanisms. An experimental study in the mononeuropathic rat.
Topics: Animals; Baclofen; Electric Stimulation; GABA Agonists; GABA Antagonists; GABA-A Receptor Agonists; | 1996 |
Spinal cord stimulation attenuates augmented dorsal horn release of excitatory amino acids in mononeuropathy via a GABAergic mechanism.
Topics: Animals; Aspartic Acid; Electric Stimulation; Excitatory Amino Acids; GABA Agents; GABA-A Receptor A | 1997 |
Spinal cord stimulation attenuates augmented dorsal horn release of excitatory amino acids in mononeuropathy via a GABAergic mechanism.
Topics: Animals; Aspartic Acid; Electric Stimulation; Excitatory Amino Acids; GABA Agents; GABA-A Receptor A | 1997 |
Spinal cord stimulation attenuates augmented dorsal horn release of excitatory amino acids in mononeuropathy via a GABAergic mechanism.
Topics: Animals; Aspartic Acid; Electric Stimulation; Excitatory Amino Acids; GABA Agents; GABA-A Receptor A | 1997 |
Spinal cord stimulation attenuates augmented dorsal horn release of excitatory amino acids in mononeuropathy via a GABAergic mechanism.
Topics: Animals; Aspartic Acid; Electric Stimulation; Excitatory Amino Acids; GABA Agents; GABA-A Receptor A | 1997 |
HIV neuropathy treated with gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 1998 |
Gabapentin for lancinating neuropathic pain.
Topics: Acetates; Acquired Immunodeficiency Syndrome; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabap | 1998 |
Modulation of spinal pain mechanisms by spinal cord stimulation and the potential role of adjuvant pharmacotherapy.
Topics: Adenosine; Animals; Baclofen; Behavior, Animal; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 1997 |
Comments on Gould, PAIN, 74 (1998) 341-343.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamm | 1998 |
Neuropathic pain after anti-HIV gene therapy successfully treated with gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 1999 |
Amino acids in spinal dorsal horn of patients during surgery for neuropathic pain or spasticity.
Topics: Amino Acids; Aspartic Acid; Chromatography, High Pressure Liquid; Extracellular Space; Feasibility S | 2000 |
Morphine and gabapentin decrease mechanical hyperalgesia and escape/avoidance behavior in a rat model of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Animals; Avoidance Learning; Cyclohexanecarboxylic Acids; Disease Mode | 2000 |
Periaqueductal grey mediated inhibition of responses to noxious stimulation is dynamically activated in a rat model of neuropathic pain.
Topics: Animals; gamma-Aminobutyric Acid; Homocysteine; Ligation; Male; Microinjections; Neural Inhibition; | 2001 |
Recurrent hypoventilation and respiratory failure during gabapentin therapy.
Topics: Acetates; Aged; Amines; Analgesics; Anti-Anxiety Agents; Anticonvulsants; Cyclohexanecarboxylic Acid | 2001 |
The putative OP(4) antagonist, [Nphe(1)]nociceptin(1-13)NH(2), prevents the effects of nociceptin in neuropathic rats.
Topics: Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Res | 2001 |
Dorsal horn synaptosomal content of aspartate, glutamate, glycine and GABA are differentially altered following chronic constriction injury to the rat sciatic nerve.
Topics: Age Factors; Animals; Aspartic Acid; Causalgia; Down-Regulation; gamma-Aminobutyric Acid; Glutamic A | 2002 |
Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain.
Topics: Animals; GABA Agonists; GABA-A Receptor Agonists; GABA-B Receptor Agonists; gamma-Aminobutyric Acid; | 2002 |